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Research summary 
 
Influenza A virus (IAV) is the causative agent of “influenza”, a febrile respiratory illness in humans. 
Yearly influenza epidemics impose a huge burden on human health and economy. Besides humans 
IAV also infects other species such as pigs and ducks and zoonotic spillovers of IAV into the human 
population can give rise to devastating pandemics.  
 
To protect itself from viral invasion and to contain viral replication, a cell produces antiviral proteins 
that inhibit the virus at different stages of its life cycle. IFITM proteins are such antiviral proteins that 
have been described to potently block cellular entry of IAV as well as many other viruses in humans 
and mice. Since very little was known on IFITM proteins present in other species that are often 
infected by IAV we studied the IFITM proteins present in swine (swIFITMs), as described in Chapter 2. 
We identified two homologues of IFITM1 and one of IFITM2 and IFITM3 respectively in porcine cells, 
and all of them were found to be upregulated upon interferon(IFN)-stimulation or IAV infection. 
Furthermore, overexpression of swIFITMs potently restricted the replication of IAV strains of human 
and porcine origin in human as well as porcine cells. Importantly, knockdown of endogenous 
swIFITMs strongly diminished the antiviral activity of IFN in porcine cells. Thus, our study 
demonstrates the relevance of swIFITM proteins as potent mediators of the antiviral IFN response in 
porcine cells.  
 
In Chapter 3 we present our studies on how IFITM proteins contribute to the cellular antiviral 
defense beyond their described function of blocking viral entry. We show that upon budding, IFITM3 
is incorporated into IAV virions and VLPs and that this incorporation is associated with a decrease in 
viral/VLP HA levels. IAV VLPs produced in the presence of IFITM3 were reduced in their entry 
efficiency, an effect that could be counteracted in a dose-dependent manner by increasing amounts 
of HA. While the infectivity of IAV virions was not impaired by the presence of IFITM3 in virus 
producer cells, they showed increased neutralization sensitivity to an HA-directed antibody which 
might be to the virus’ detriment in an in vivo situation. Hence, we provide evidence that in addition 
to blocking viral entry, IFITM3 contributes to the antiviral defense during late stages of IAV infection 
by increasing the virus’ neutralization sensitivity. 
 
In summary, the here presented studies establish swIFITM proteins as potent and relevant antiviral 
restriction factors and identified a role for IFITM3 during late stages of the IAV life cycle.  
3 
 
Zusammenfassung 
 
Der Influenza A Virus (IAV) ist der Erreger der Grippe (med. Influenza), einer fiebrigen Erkrankung der 
Atmungsorgane des Menschen. Jährlich wiederkehrende Grippeepidemien belasten sowohl die 
menschliche Gesundheit als auch die Wirtschaft. IAV zirkuliert nicht nur im Menschen sondern auch 
in verschiedenen Tierarten, wie beispielsweise Schweinen und Enten. Dabei können sogenannte 
zoonotische Infektionen, Infektionen von Menschen mit einem Virus tierischen Ursprungs, 
verheerende Pandemien auslösen. 
 
Um sich vor Viruserkrankungen zu schützen, und um die Virusreplikation im Falle einer Infektion 
einzudämmen, werden in der Zelle sogenannte antivirale Proteine produziert. Diese hemmen 
verschiedene Stadien des viralen Lebenszyklus. IFITM Proteine sind solche antiviralen Proteine, die 
das Eindringen von IAV, aber auch diversen anderen Viren, in Menschen – oder Mauszellen zu 
verhindern. Da nur sehr wenig bekannt war über IFITM Proteine in anderen Spezies, die oft von IAV 
infiziert werden, haben wir die IFITM Proteine im Schwein (swIFITMs) untersucht, wie in Kapitel 2 
beschrieben. Dabei identifizierten wir in Schweinezellen zwei Homologe von IFITM1, und je eines von 
IFITM2 und IFITM3, die alle durch Interferon-Stimulation oder IAV Infektion induziert wurden. Zudem 
konnten wir zeigen, dass die Replikation von IAV Stämmen menschlichen oder porcinen Ursprungs 
durch die Überexpression von swIFITMs in humanen als auch porcinen Zellen gehemmt wurde. 
Bedeutenderweise führte das Stilllegen endogener swIFITM Proteine zu einer starken Verminderung 
der antiviralen Aktivität von Interferon in porcinen Zellen, womit diese Studie die Relevanz von 
swIFITM Proteinen als wichtige Bestandteile der Interferonantwort in porcinen Zellen demonstriert.  
 
In Kapitel 3 beschreiben wir, wie IFITM3 zur zellulären antiviralen Abwehr jenseits der Hemmung des 
viralen Eintritts in die Zelle beiträgt. Wir zeigen, dass IFITM3 sowohl in Influenza virusähnliche 
Partikel (VLP), als auch in IAV Partikel eingebaut wurde, und dass dieser Einbau mit einer Reduktion 
des Hemagglutinin (HA) Levels einherging. Wurden VLPs in der Gegenwart von IFITM3 produziert, 
reduzierte sich dadurch ihre Infektiösität. Dem konnte jedoch durch Erhöhung der HA Level in VLP-
produzierenden Zellen in dosisabhängiger Weise entgegengewirkt werden. Während, im Gegensatz 
zu VLPs, die Infektiösität von IAV Partikeln durch die Gegenwart von IFITM3 in Virus-produzierenden 
Zellen nicht gemindert wurde, waren diese IAV Partikel anfälliger für neutralisierende, gegen HA 
gerichtete Antikörper, was dem Virus in vivo potentiell nachteilig sein könnte. Somit konnten wir 
zeigen, dass IFITM3 zusätzlich zur Hemmung des viralen Eintritts in die Zelle, durch die Erhöhung der 
Empfindlichkeit des Virus gegenüber neutralisierenden Antikörpern, zur antiviralen Abwehr während 
späten Stadien des viralen Lebenszyklus beiträgt. 
  
 
Zusammengefasst demonstrieren die hier präsentierten Studien die Relevanz von swIFITM Proteinen 
als wirksame antivirale Faktoren und offenbaren eine Rolle für IFITM3 während späten Stadien des 
viralen Lebenszyklus. 
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Abbreviations 
 
25HC 25-hydroxycholesterol 
BlaM1 β-lactamase-M1 
BSA bovine serum albumin 
CARD caspase-recruitment domain 
CH25H cholesterol-25-hydroxylase 
CME clathrin-mediated endocytosis 
COPI coat protein I 
CPZ chlorpromazine 
CRM1 chromosome maintenance region 1 
cRNA complementary RNA 
CT cytoplasmic tail 
DC dendritic cell 
DMEM Dulbecco's Modified Eagle's Medium 
EGFR epidermal growth factor receptor 
EIF2α eukaryotic translation initiation factor 2α 
Env envelope glycoprotein 
ER endoplasmic reticulum 
FCS fetal calf serum 
Fig. figure 
FPPS farnesyl diphosphate synthase 
FRAP fluorescence recovery after photobleaching 
GAF IFN-γ activation factor 
GAP GTPase activating protein 
GAS gamma-activated sequence 
GPI glycophosphatidylinositol 
HA hemagglutinin 
HCMV human cytomegalovirus 
HCoV-OC43 human coronavirus OC43 
HIV human immunodeficiency virus 
HL hemagglutinin-like 
HPAI highly pathogenic avian influenza 
HTBE human tracheobronchial epithelial cell 
IAV influenza A virus 
  
 
IFITM interferon-induced transmembrane protein 
IFN interferon 
IFNAR IFN-α receptor 
IFNGR IFN-γ receptor 
IFNLR IFN-λ receptor 
IRF IFN-regulatory factor 
ISG IFN-stimulated gene 
ISRE IFN-stimulated response elements 
JAK Janus kinase 
JSRV Jaagsiekte sheep retrovirus 
LBPA lysobisphosphatidic acid 
LPAI low pathogenic avian influenza 
LRR leucine-rich repeats 
M1 matrix 1 protein 
M2 matrix 2 protein 
MAPK mitogen-activated protein kinase 
MAVS mitochondrial antiviral-signaling protein 
MDCK cells Madin Darby canine kidney cells 
MOI multiplicity of infection 
MTOC microtubule organizing centre 
Mx myxovirus resistance protein 
NA neuraminidase 
NEP nuclear export protein 
NES nuclear export signal 
NL neuraminidase-like 
NLRP NOD-like receptor Family Pyrin Domain 
NLS nuclear localization signal 
NP nucleoprotein 
NPC nuclear pore complex 
NPTr cells newborn pig trachea cells 
NS1 non-structural protein 1 
NS2 non-structural protein 2 
NSK cells newborn swine kidney cells 
OA oleic acid 
OAS oligoadenylate synthetase 
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ORF open reading frame 
OSBP oxysterol-binding protein 
p.i. post infection 
p.i.DMEM post infection Dulbecco's modified Eagle's medium 
PAMP pathogen-associated molecular patterns 
PBSi infection PBS 
pDC plasmacytoid DC 
PEI polyethylenimine 
PK15 cells porcine kidney 15 cells 
PKR protein kinase R 
poly(I:C) polyinosinic:polycytidylic acid 
PRR pattern-recognition receptors 
Rack1 protein C kinase 1 
RIG-I retinoic acid-inducible gene I 
Rr Pearson correlation coefficient 
RSV respiratory syncytial virus 
RTK receptor tyrosine kinase 
SeV Sendai virus 
sialic acid N-acetylneuraminic acid 
SNP single nucleotide polymorphism 
STAT Signal Transducers and Activators of Transcription 
suppl. supplementary 
swIFITM swine interferon-induced transmembrane protein 
TEM transmission electron microscopy 
TGN trans-Golgi network 
TLR Toll-like receptor 
TMD transmembrane domain 
TYK tyrosine kinase 
VAPA vesicle-membrane protein-associated protein A 
VLP virus-like particle 
vRNP viral ribonucleoprotein 
w/v weight per volume 
WSN A/WSN/33 
wt wild type 
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Chapter 1 
 
INTRODUCTION 
1.1 INFLUENZA VIRUS – A GENERAL INTRODUCTION 
„Influenza“ or shortly „the flu“ describes a febrile respiratory illness in humans caused by influenza 
viruses [1]. Historical reports describing the occurrence of influenza-like diseases in humans and 
animals date back to the middle ages [2], suggesting that influenza viruses have been circulating for 
centuries. They impose a huge burden on human health and economy by causing seasonal epidemics 
that lead to the hospitalization of over 200’000 and the death of 30’000-50’000 people in the U.S. 
every year [4].  
Based on their genome and protein composition influenza viruses can be classified into types A, B 
and C [1]. While type A has been shown to infect a wide variety of species such as humans, birds, 
pigs, seals, horses and dogs [7], type B and C have been found to be primarily human viruses [1].  
Influenza A virus (IAV) strains are categorized into different subtypes according to their envelope 
glycoproteins hemagglutinin (HA) and neuraminidase (NA), their main antigenic determinants. 
Aquatic birds are the natural reservoir for IAV, and currently there are 16 different HA and 9 different 
NA subtypes circulating [1, 8]. Recently, IAV-like virus sequences were isolated from Central and 
South American bat species. The high seroprevalence of these IAV-like viruses in multiple bat species 
suggests that bats may represent another reservoir for influenza viruses [9, 10]. Interestingly, the bat 
HA-like (HL) H17 and H18 proteins lack sialic-acid binding, while bat NA-like (NL) N10 and N11 
proteins lack neuraminidase function [11]. HL17NL10 and HL18NL11 have recently been rescued 
from synthetically derived cDNA and await their further characterization [12]. First studies performed 
with chimeric viruses harboring six bat IAV-like genes and HA and NA genes from a prototypic IAV 
strain showed no reassortment between bat IAV-like and prototypic IAV strains, suggesting that 
zoonotic IAV transmissions from bats to humans are not very likely to occur [13]. In contrast, 
reassortment between avian or porcine and human IAV strains does occur. The introduction of novel 
HAs into IAV strains circulating in humans can lead to pandemics due to the lack of protecting 
antibodies present in the population. This is exemplified by the “swine flu” pandemic in 2009/2010 
that was caused by a reassortant H1N1 IAV that harbored an HA gene from swine IAV.  
Currently IAV are kept in check by protective vaccination and, in case of infection, antiviral therapy. 
However, vaccination, as well as antiviral therapy have their shortcomings. Due to the high mutation 
rate in influenza viruses vaccinations need to be adapted every season to match the currently 
circulating virus strains. Current antiviral drugs include M2 ion channel inhibitors and neuraminidase 
inhibitors. However, resistance against ion channel inhibitors is widespread and can also arise against 
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neuraminidase inhibitors given the high mutation rate observed in IAV [14], highlighting the need for 
further understanding of the interplay between influenza viruses and their hosts to develop 
additional strategies to combat these viruses. 
 
 
1.2 CLASSIFICATION & ARCHITECTURE OF INFLUENZA A VIRUS VIRIONS 
IAV belongs to the family of Orthomyxoviridae, whose members are characterized by their single-
stranded segmented RNA genome of negative sense [15]. Unlike most other RNA viruses, IAV 
genome transcription and replication take place in the nucleus of infected cells [16-18]. As a 
consequence, the virus benefits from access to the cellular splicing and 5’-cap machinery which 
increases its coding capacity [19]. 
 
The genome of IAV consists of 8 viral RNA segments, each of which is associated with an RNA-
dependent RNA polymerase complex composed of PB1, PB2 and PA. The viral RNA itself is 
encapsidated by the nucleoprotein (NP). Viral RNA segments associated with their RNA polymerase 
and bound by NP are referred to as viral ribonucleoproteins (vRNPs) [20]. IAV is an enveloped virus 
that derives its membrane from its host cell upon budding. On the inside of the virions this 
membrane is lined by the viral matrix protein M1, as depicted in Figure 1 [15]. The only viral proteins 
exposed on the virion’s surface are the hemagglutinin (HA), neuraminidase (NA) and matrix 2 (M2) 
proteins. While HA is responsible for the attachment of the virus to its cellular receptor sialic acid, NA 
cleaves the binding between HA and sialic acid and thus enables the release of budding viruses from 
the sialic acid containing surface of the virus-producing cell. M2 is a transmembrane protein forming 
ion channels in the viral membrane that allow the acidification of the virion core as the virus travels 
along the endocytic route. This acidification is thought to be required to weaken electrostatic 
interactions between M1 and vRNPs, thus facilitating the cytosolic release of vRNPs upon membrane 
fusion [21, 22].  
 
Besides the structural proteins the virus also codes for several non-structural proteins that are 
expressed upon viral infection. mRNA transcribed from the NS segment is translated to the non-
structural protein 1 (NS1) if unspliced, while the spliced mRNA gives rise to the non-structural protein 
2 (NS2), also described as nuclear export protein (NEP). NS1 plays important roles in antagonizing the 
host’s antiviral immune response, both by limiting the induction of the interferon (IFN) response and 
by blocking the antiviral proteins PKR and OAS. Furthermore, NS1 is involved in a plethora of 
different functions such as inhibition of cellular mRNA processing and export and activation of PI3K 
  Chapter 1 
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[23]. NS2/NEP is required for the nuclear export of vRNPs [24]. In addition, it has been shown to 
regulate viral RNA transcription and replication [25].  
The +1 reading frame of the PB1 gene segment gives rise to PB1-F2, a short peptide whose 
interaction with mitochondria leads to cytochrome c release and apoptosis in infected cells [26, 27]. 
Furthermore, PB1-F2 has been associated with an increase in inflammation and secondary bacterial 
infection in infected mice [28]. PB1 N40 is the third open reading frame (ORF) known to be translated 
from the PB1 mRNA to date. PB1 N40 arises through differential usage of start codons, resulting in a 
truncated version of PB1 that lacks its first 40 amino acids. PB1 N40 interacts with PB2 and PA, but 
fails to reconstitute a functional polymerase complex. It is non-essential for the virus but its loss can 
impair viral replication [29].  
Spliced mRNA transcribed from the PB2 gene segment is translated to PB2-S1. Harboring an internal 
deletion, this form of PB2 localizes to mitochondria and has been reported to interfere with viral 
polymerase activity and the RIG-I-induced induction of IFN signaling. However, viruses lacking PB2-S1 
show normal growth kinetics and immunopathology [30]. 
Apart from the RNA polymerase component PA, the PA gene segment has been reported to give rise 
to 3 additional viral proteins. The PA-X protein, consisting of the PA N-terminal and an alternative C-
terminal domain results from ribosomal frameshifting. PA-X has been described to be involved in 
host-cell shutoff and viral immunopathology [31]. Usage of alternative in-frame AUG start codons 
yields PA-N155 and PA-N182. These truncated forms of PA do not show polymerase activity, 
however, in their absence viruses grow slower in tissue culture and show decreased pathogenicity in 
mice [32].  
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Figure 1: The structure of an IAV virion. IAV is enveloped by a host-
cell-derived lipid membrane that harbors the surface glycoproteins HA 
and NA and the M2 ion channel. The segmented RNA genome of 
negative sense is tightly bound by NP proteins and associated with the 
polymerase complex consisting of PA, PB1 and PB2. M1 lines the 
inside of the virion, interacting with vRNPs and the viral envelope. [5] 
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1.3 THE INFLUENZA A VIRUS LIFE CYCLE 
1.3.1 IAV BINDING TO HOST CELLS 
The viral entry process is initiated upon engagement of HA glycoprotein trimers with their cellular 
receptor N-acetylneuraminic acid (sialic acid) [15, 33]. Sialic acids are typically linked to galactose and 
terminate oligosaccharide chains attached to cellular proteins [34]. While human IAV isolates 
preferentially bind to α2,6-linked sialic acids that are displayed in the human upper respiratory tract 
[35, 36], avian isolates show predominant binding to glycans displaying α2,3-linked sialic acids that 
are found in the gastrointestinal tract of birds [35, 37, 38]. 
HA is translated from HA mRNA as HA0, the uncleaved HA precursor. HA0 trimerizes in the 
endoplasmic reticulum (ER) before being routed to the cellular surface via the Golgi apparatus [39]. 
To become fusogenic, HA0 needs to be cleaved into its subunits HA1 and HA2 [40]. While HA1 
harbors receptor-binding moieties, HA2 carries a hydrophobic fusion peptide at its N-terminus which 
is inserted into the target cell membrane upon fusion [41]. Cleavage of HA0 occurs at a specific 
arginine residue and is exerted by proteases present in either the trans-Golgi network, such as 
TMPRSS2, or on the cellular surface, as for example HAT [41]. The presence or absence of suitable 
proteases able to cleave HA0 affects virus tropism and systemic spread [40]. 
 
1.3.2 IAV ENDOCYTOSIS AND ENDOSOMAL TRAFFICKING 
There are several ways for viruses get endocytosed into their target cells. Pinocytosis, the cellular 
uptake of extracellular fluid and its contents, can be divided into four distinct processes: clathrin-
mediated endocytosis (CME), caveolae-mediated endocytosis, clathrin – and caveolae independent 
endocytosis and macropinocytosis [42]. CME describes the process of invagination of clathrin-coated 
pits at the plasma membrane that pinch off into the cytoplasm giving rise to clathrin-coated vesicles 
[43]. Caveolae-mediated endocytosis occurs at caveolin-1-enrichted domains of lipid rafts [44]. CME 
as well as caveolae-mediated endocytosis are dependent on dynamin, a GTPase that mediates 
scission of vesicles off the plasma membrane [45, 46]. In addition, several clathrin – and caveolin-
independent endocytosis pathways have been described but their characterization remains 
challenging due to lack of suitable protein markers [47]. Stimulation of cells (for example by growth 
factors) can lead to “membrane ruffling”consisting of actin-driven protrusions of membranes. When 
collapsing onto and fusing with the plasma membrane, these protrusions engulf extracellular 
material, a process referred to as micropinocytosis [42].  
Early electron microscopy experiments provided evidence that IAV can enter target cells via CME. 
However, the same studies also observed IAV present in uncoated vesicles and cell surface 
invaginations, suggesting IAV also uses pathways other than CME for cellular entry [48]. Indeed, 
blocking CME by treating cells with the CME inhibitor chlorpromazine or introducing a dominant-
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negative mutant of a protein needed for CME (Eps15) did not inhibit IAV infection. Furthermore, IAV 
infection was left largely unaffected when caveolin-mediated endocytosis was prevented by treating 
cells with cholesterol-sequestering drugs (nystatin, methyl-β-cyclodextrin) [49]. A recent study 
corroborates the involvement of macropinocytosis in IAV cellular entry. In the presence of fetal calf 
serum IAV entry is completely abolished only if both, CME and macropinocytosis, are blocked by 
either chemical inhibitors or dominant-negative mutants [50].  
 
For viruses entering via CME it has been observed that clathrin-coated pits form de novo at the site 
of viral attachment [51]. Epsin1, an adaptor protein able to interact with clathrin, ubiquitin and 
phospholipids has been shown to be recruited to these viral attachment sites and identified as 
essential for CME of IAV but not for other substrates of CME [52]. This suggests that viral cues are 
necessary for a successful entry process. However, how viral attachment is sensed and how the 
uptake of the virus is triggered remains elusive. Nevertheless, several studies provided evidence that 
downstream signaling processes do play a role in the uptake of IAV. The protein and lipid kinase PI3K 
is involved in several cellular processes such as growth, metabolism and survival. Interestingly, PI3K 
seems to regulate early steps of viral infection. Blocking PI3K with its inhibitor wortmannin prior to or 
early in infection reduced viral titers, while titers remained largely unaffected upon PI3K blockage 
later in infection [53]. IAV binding and PI3K activation might be linked through the activation of 
receptor tyrosine kinases (RTKs). Indeed, tyrosine kinase activity has been shown to be required for 
IAV uptake [54] and the RTK epidermal growth factor receptor (EGFR) was found to be involved in 
IAV uptake. Since the multivalent binding of IAV to target cells was found to lead to the clustering of 
lipid rafts, and EGFR is localized to those, the authors of this study speculated that lipid raft clusters 
might serve as signaling platforms activating RTKs required for viral uptake [54].  
 
The endosomal system regulates the cellular distribution of vesicles and can be divided into three 
compartments: early endosomes, late endosomes and lysosomes. The early endosomes, localized 
close to the plasma membrane, are primarily responsible for protein sorting. Endosomal cargo can 
either be routed back to the plasma membrane via recycling endosomes (often happening for 
receptors displayed at the plasma membrane) or be sent along the endosomal pathway towards late 
endosomes and lysosomes localized in nuclear proximity [55]. Specificity of vesicular transport is 
ensured by Rab proteins. These monomeric GTPases selectively bind to specific vesicular membranes 
and mediate their transport and fusion. While Rab5 is associated with early endosomes, Rab7 is a 
marker for late endosomes [43]. Experiments performed with dominant-negative forms of Rab5 and 
Rab7 showed that IAV infection requires Rab5 as well as Rab7, confirming that IAV moves via early to 
late endosomes [56]. As endosomes mature travelling along the endocytic route their internal pH is 
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continuously decreased by V-ATPases that pump protons across their membrane [57]. IAV need to 
reach late endosomes where they are exposed to a low pH triggering conformational changes in HA 
that lead to fusion of the viral with the endosomal membrane [48, 58, 59].  
 
1.3.3 IAV FUSION AND UNCOATING 
When exposed to the acidic pH occurring in late endosomes, cleaved HA undergoes an irreversible 
conformational change that leads to the insertion of its hydrophobic fusion peptide (the N-terminal 
part of HA2) into the target cell membrane [39, 60-62]. To induce fusion between the viral and the 
target cell membrane HAs tilt, bringing the two membranes into close proximity [63]. Finally, 
membranes start to fuse and it is thought that a ring of fusogenic HA trimers locally limiting lipid flux 
allows for the opening of a fusion pore through which vRNPs are delivered to the cytoplasm [39, 64].  
Acidification of endosomes is not only required to trigger HA-mediated fusion, but also to weaken 
interactions between vRNPs and M1. The M2 ion channel pumps protons into the viral lumen, 
inducing a conformational change in M1 that leads to its dissociation from vRNPs. Free vRNPs can 
then be delivered to the cytoplasm and this process is called uncoating [65-68]. 
 
1.3.4 VRNP NUCLEAR IMPORT 
As a nuclear-replicating virus, IAV needs to deliver its genome into the host cell’s nucleus for 
successful viral replication [16]. While small proteins can pass the nuclear membrane via passive 
diffusion, larger proteins and complexes need to interact with the nuclear import machinery to be 
funneled through nuclear pore complexes [19]. It has been shown that naked IAV RNA is no substrate 
for nuclear translocation but needs to be bound by NP to get imported into the nucleus. NP harbors 
nuclear localization signals (NLS) that mark it as substrate for nuclear import [69]. Importantly, these 
NLS are masked by binding of M1 to NP, highlighting the importance of the uncoating process [19]. 
The other components of the vRNP, PB1, PB2 and PA, have also been shown to harbor NLS [70-72]. 
However, to date it is not known whether those also contribute to vRNP import.  
 
1.3.5 TRANSCRIPTION AND REPLICATION OF THE IAV GENOME 
Once inside the nucleus, the viral genome is transcribed into mRNA in a process called primary 
transcription. Due to its RNA genome of negative polarity IAV cannot make use of the host cell’s 
transcription machinery, but relies on its RNA-dependent RNA polymerase complex composed of 
PB1, PB2 and PA [73]. Deficient in mRNA 5’-capping, IAV performs the so-called “cap-snatching” to 
get access to 5’-capped mRNA primers. While PB2 and PA have both been shown to bind to host-
derived 5’-capped mRNA, endonuclease function necessary to cleave off 5’-capped mRNA primers 
has been mapped to PA [73-75]. PB1 in turn has been found to be responsible for mRNA chain 
elongation and harbors the actual RNA polymerase function [76]. It is thought that the polymerase 
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complex remains associated with the 5’ end of the viral RNA, while the template is funneled through 
the PB1 active site in the 3’-5’ direction, giving rise to nascent mRNA. Once the polyU sequence, 
encoded approximately 16 nucleotides from the vRNA 5’ end, reaches the PB1 active site, the 
template cannot be funneled any further due to sterical hindrance. Template slipping on the polyU 
sequence subsequently leads to the addition of a polyA tail to the viral mRNA [73]. Although not 
resolved entirely, there is evidence for viral mRNAs using the normal host cell machinery for splicing, 
nuclear export and translation [77].  
 
To generate a template for viral genome replication, vRNA is first transcribed into complementary 
RNA (cRNA). cRNA lacks a 5’-cap as well as a polyA tail and is thus distinct from viral mRNA [73]. 
Although still under debate, there is strong evidence for a model explaining the switch from mRNA to 
cRNA production. In this model, vRNA is transcribed to mRNA by the incoming polymerase associated 
with the viral RNA during infection, while cRNA production is mediated by newly produced 
polymerase complexes [78, 79]. Fittingly, de novo synthesis of viral proteins has been found 
necessary for viral genome replication [80]. Interestingly, other studies also highlight the importance 
of viral protein synthesis for genome replication, but they hypothesize that cRNA is rapidly degraded 
by endonucleases if not stabilized by NP and the polymerase complex [81].  
 
1.3.6 LATE STAGES OF THE IAV LIFE CYCLE 
After successful genome replication vRNPs need to be transported out of the nucleus and trafficked 
to the plasma membrane where virus assembly takes place. Similarly, viral structural proteins and 
envelope glycoproteins need to be localized to virus assembly sites to allow the formation of new IAV 
particles and their budding from the plasma membrane. Current knowledge on late stages of the IAV 
life cycle and the interplay between IAV and its host is summarized in chapter 5 in the review from 
Pohl, M.O., Lanz, C. and Stertz, S. Late stages of the influenza A virus replication cycle – a tight 
interplay between virus and host. J Gen Virol, 2016 that I contributed to [82].  
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Figure 2: The IAV life cycle. After receptor-mediated endocytosis, IAV travels 
along the endocytic route. Upon acidification in late endosomes HA undergoes 
a conformational change, leading to fusion between the viral and the 
endosomal membrane. vRNPs are subsequently released into the cytoplasm 
and trafficked to the nucleus, where primary transcription and replication take 
place. Early proteins are translocated to the nucleus where they are involved 
in genome replication and vRNP assembly. Finally, vRNPs and viral proteins 
are trafficked to the plasma membrane, where new IAV virions bud from lipid 
rafts [3]. 
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1.4 THE ZOONOTIC POTENTIAL OF INFLUENZA A VIRUS 
IAV has been shown to infect various animal species such as birds, swine, dogs, horses and bats [7]. 
Although IAV strains are highly adapted to their hosts in terms of receptor binding, host factor usage 
and counteraction of the immune system (among others), occasional “jumps” of IAV from one 
species to another occur [7, 83]. Due to their segmented genome IAV strains can reassort when 
infecting the same cell [15, 84]. Invading viruses can thus swap gene segments with viruses already 
circulating in and thus adapted to the host [85, 86]. Together with the fact that IAVs harbor an error-
prone RNA-dependent RNA polymerase [87] this facilitates and accelerates the emergence of IAV 
strains adapted to replicate in a new host [85, 86].  
Historically, this proved especially fatal when IAV crossing the species barrier displayed HAs the 
population was immunologically naïve to [7]. From 1918-1919, the pandemic known as “The Spanish 
Flu” caused by an avian-like H1N1 IAV strain killed approximately 50 million people. While the 
pandemic potential of this virus can be explained by the lack of protecting antibodies circulating in 
the population, its unprecedented severity remains a matter of study [3]. Since then, the human 
population repeatedly suffered from pandemics caused by human/avian or human/avian/swine IAV 
reassortants [3, 7].  
Pigs have been hypothesized to play a crucial role in giving rise to human IAV pandemics. They have 
been shown to display α2,3 – as well as α2,6-linked sialic acid residues in the trachea, which renders 
them susceptible to infection with avian IAV strains that preferentially bind to α2,3-linked sialic acid, 
as well as human IAV strains showing preferential binding to α2,6-linked sialic acid [88]. This is 
exemplified by the pandemic H1N1 IAV strain that started to circulate in the human population in 
2009 . IAV from porcine, avian and human origin gave rise to a triple-reassortant virus maintained in 
pigs. Further reassortment with an avian-like swine IAV finally yielded an IAV strain able to ignite a 
pandemic in humans (Fig. 3) [3]. Importantly, reassortment in pigs does not seem to be a 
prerequisite for avian or swine IAV to infect humans, as several direct transmission events suggest 
[89-94]. However, none of those resulted in sustained IAV human-to-human transmission [7]. 
Concludingly, to detect potentially pandemic zoonotic IAV strains as early as possible, careful 
monitoring of the circulating IAV strains is necessary [95]. Nevertheless, since vaccine production 
may take too long and antiviral drugs may not be effective or sufficiently available in case of a 
pandemic, research focusing on a vaccine that induces broadly-neutralizing antibodies against IAV is 
driven forward [3, 96]. 
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Figure 3: The source of swine-origin 2009 pandemic H1N1 IAV. IAV 
strains from porcine, avian and human origin gave rise to a triple-
reassortant IAV strain in pigs. Subsequent reassortment with an 
Eurasian avian-like IAV strain yielded the 2009 pandemic H1N1 IAV 
strain. [3] 
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1.5 THE INTERFERON SYSTEM 
1.5.1 INTRODUCTION 
The concept of “viral interference”, the observation that infection of a bacterial, plant or animal cell 
with a virus can protect this cell from further viral infection [97] led the foundation for the discovery 
of the interferon system. Groundbreaking work performed by Isaacs and Lindenmann [98, 99] in the 
1950s led to the discovery of interferon (IFN), described as a factor released from chick chorio-
allantoic membrane upon incubation with heat-inactivated IAV that could interfere with IAV infection 
in a fresh piece of chorio-allantoic membrane. Further studies showed that IFNs are proteins 
secreted by one cell upon detection of pathogen-associated molecular patterns (PAMPs) and sensed 
by another through binding to specific receptors. IFN signaling results in the transcription of 
interferon-stimulated genes (ISGs) that induce an antiviral state, but also affects numerous cellular 
processes such as motility, proliferation and immunological responses [100, 101]. Based on their 
receptor usage, IFNs can be divided into three classes: type I, type II and type III IFNs. Type I IFNs 
signal through the IFN-α receptor 1 (IFNAR1)/IFN-α receptor 2 (IFNAR2) heterodimeric receptor 
complex and comprise IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω in humans [6]. These different IFN 
subclasses induce distinct cellular functions thought to be mediated at least partially by differential 
receptor affinity and stability of the IFN/IFNAR complexes [102, 103].  
The homodimeric IFN-γ, signaling through the IFN-γ receptor (IFNGR), is the only member of type II 
IFN known to date. IFN-γ is mainly produced by immune cells, but can be sensed by a wide variety of 
target cells, especially in epithelial tissues [104].  
Type III IFNs comprise IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4 [105-107]. Distantly related to the IL-10 
family of interleukins, type III IFNs signal through heterodimeric complexes of IL-10R2 and IFN-λ 
receptor 1 (IFNLR1) [105, 106]. Only epithelial cells have been found to be responsive to IFN-λ, 
possibly protecting the host from pathogens infecting through mucosal surfaces [108].  
 
1.5.2 IFN SIGNALING 
All types of IFN rely on the Janus kinases (JAKs) and the Signal Transducers and Activators of 
Transcription (STATs) to translate the binding of IFN receptors by their ligands into a cellular 
response, as depicted in Figure 4. JAKs involved in IFN signaling comprise JAK1, JAK2 and tyrosine 
kinase 2 (TYK2) and are associated with the cytoplasmic portion of IFN receptor chains [6]. All STATs 
known to be expressed in mammals (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) seem 
to participate in innate immune signaling [109]. However, mainly STAT1 and STAT2 have been found 
to be involved in IFN signaling.  
Upon binding of IFN to its receptor, the individual receptor chains are brought closely together, 
resulting in the juxtaposition of the associated JAKs that subsequently undergo transphosphorylation 
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and thus activation [110, 111]. Activated JAKs phosphorylate their IFN receptor chains, generating a 
binding interface for SH2-domains on STAT proteins. Binding of STAT proteins to the IFN receptor 
chains brings them into close proximity of and leads to their phosphorylation by JAKs. 
Phosphorylated STATs form homo – or heterodimers that translocate to the nucleus where they 
drive the expression of IFN-stimulated genes (ISGs) [110, 112].  
More precisely, signaling via type I and type III IFN leads to the formation of phospho-
STAT1/phospho-STAT2 heterodimers that recruit the IFN-regulatory factor 9 (IRF9), combining into 
the IFN-stimulated gene factor 3 (ISGF3). ISGF3 translocates to the nucleus and binds to IFN-
stimulated response elements (ISRE) that are localized upstream of ISGs. In contrast, type II IFN 
signaling leads to the formation of homodimers of phospho-STAT1 called IFN-γ activation factor 
(GAF). GAF also translocates to the nucleus, but instead of binding to ISRE it binds to gamma-
activated sequence (GAS) promoters that drive the expression of GAS-responsive ISGs [6].  
 
 
 
 
 
 
 
Figure 4: The interferon (IFN) signaling pathway. Type I, II and III IFN bind to and signal 
via specific IFN receptors. Binding of IFNs to their cognate receptors triggers the 
autophosphorylation of receptor-associated kinases that in turn phosphorylate specific 
receptor residues, enabling the recruitment and phosphorylation of STAT proteins. Type 
I and III IFN signaling results in the formation of phosphorylated STAT1-STAT2 
heterodimers that associate with IRF9 to translocate to the nucleus to initiate ISRE-
mediated transcription of ISGs. In contrast, type II IFN signaling results in the formation 
of phosphorylated STAT1 homodimers that drive GAS-mediated transcription of ISGs. [6] 
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Importantly, the interferon signaling cascade described here is simplified. Some examples for more 
elaborate mechanisms include IRFs recognizing parts of ISREs, cooperation of STATs with other 
transcription factors (such as IRFs) and epigenetic modifications of DNA stretches accessed by STATs. 
This drastically increases the complexity but also the potential for fine-tuning of the system [113]. 
 
1.5.3 INNATE IMMUNE SIGNALING UPON IAV INFECTION 
To sense invading pathogens cells are equipped with so-called pattern-recognition receptors (PRRs) 
that induce immune signaling upon detection of non-self motifs, called pathogen-associated 
molecular patterns (PAMPs) [114]. These PAMPs include for example the lipopolysaccharides 
displayed on the membrane of Gram-negative bacteria or dsRNA present during viral infections [115, 
116]. Several PRRs are involved in the sensing of IAV and are discussed in the following sections. 
 
1.5.3.1 TOLL-LIKE RECEPTORS (TLRS) 
TLRs are transmembrane proteins harboring a ligand-binding domain at the N – and a cytoplasmic 
signaling domain at the C – terminus [117]. TLR3 has been shown to localize to endosomes [118], 
where it detects dsRNA and subsequently induces the production of type I interferons and NF-κB-
dependent transcription [119]. In agreement with the fact that no dsRNA should be exposed on 
endosomal incoming IAV particles it has been shown that TLR3 activation in dendritic cells (DCs) 
depends on phagocytosis of infected cells [120] that have been hypothesized to contain RNA 
structures able to induce TLR3 signaling [121]. In contrast, TLR7, another endosomally localized TLR, 
has been found to directly respond to IAV by sensing ssRNA upon infection of plasmacytoid DCs 
(pDCs). Subsequent immune signaling leads to type I IFN and inflammatory cytokine production [122, 
123]. The authors hypothesize that endosomal proteases might lead to a certain degree of IAV 
degradation, thereby exposing its ssRNA genome [122].  
 
1.5.3.2 RETINOIC ACID-INDUCIBLE GENE I (RIG-I) 
Studies performed in RIG-I deficient mouse fibroblasts and DCs established this cytosolic RNA 
helicase as an important mediator of type I IFN signaling upon RNA virus infection [124]. More 
precisely, RIG-I has been shown to get activated by virus-specific 5’-mono and -triphosphate ssRNA 
[125-127]. However, also dsRNA and polyU sequences have been shown to trigger RIG-I-mediated 
signaling [128-130]. ATP is recruited to RIG-I upon binding of viral RNA, facilitating a conformational 
change liberating RIG-I’s caspase-recruitment domains (CARDs) [115, 131, 132]. CARDs subsequently 
interact with mitochondrial antiviral signaling (MAVS) adaptor proteins, resulting in the recruitment 
of a myriad of signaling molecules leading to NF-κB-, IRF3-, and IRF7-dependent transcription of 
antiviral genes [128, 133].  
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The importance of RIG-I in the antiviral immune response against IAV has been corroborated by the 
finding that IAV evolved measures to counteract its action: NS1 has been shown to bind to RIG-I, 
thereby inhibiting its activation [125].  
 
1.5.3.3 NOD-LIKE RECEPTOR FAMILY PYRIN DOMAIN CONTAINING 3 (NLRP3) 
Nucleotide-binding oligomerization domain-like receptors (NOD-like receptors or NLRs) are cytosolic 
PRRs expressed in immune as well as epithelial cells. They harbor a variable effector domain in their 
N-terminus and leucine-rich repeats (LRRs) in their C-terminus that are responsible for ligand binding 
[134]. Stimulation of NLRs induces the formation of the so-called “inflammasome”: the 
oligomerization of NLRs and their association with adaptor proteins and pro-caspases. The 
subsequent activation of caspases promotes the maturation of the proinflammatory cytokines pro-IL-
1β and pro-IL-18 into their mature forms that can then be secreted [135].  
NLRP3 is an NLR harboring a pyrin domain in its effector domain [136]. Upon IAV infection, this pyrin 
domain interacts with the pyrin domain of its adaptor protein, the inflammasome is assembled and 
pro-inflammatory cytokines are secreted [137]. Two components of IAV have been observed to 
induce NLRP3 activation: ssRNA [138] and PB1-F2 [139]. Furthermore, M2 ion channel activity in IAV-
infected cells has been shown to trigger NLRP3 activation, possibly through proton imbalance in the 
cytoplasm [140]. Nlrp3 knockout mice have been shown to be compromised in their immune 
response upon IAV infection, which was associated with an increase in mortality, highlighting 
NLRP3’s relevance in vivo [141].  
 
Although countless in vitro and in vivo studies established the importance of the different PRRs in 
sensing IAV in order to mount an antiviral immune response, the individual contribution of and 
potential redundancies between different PRRs are not resolved entirely and have been described to 
be cell type-dependent [124]. 
 
 
1.5.4 SELECTED ISGS WITH ACTIVITY AGAINST IAV 
1.5.4.1 MYXOVIRUS RESISTANCE PROTEIN (MX) 
The observation that mice of a particular strain survived IAV challenges found to be lethal in other 
strains led to the discovery of Myxovirus resistance protein 1 (Mx1) [142]. Mx1 is expressed in wild 
mice but absent from most laboratory mouse strains due to deletions and nonsense mutations in the 
Mx1 locus [143, 144].  
Mx proteins are dynamin-like GTPases induced by type I and type III IFN [145]. In mice, Mx1 has been 
identified as one of the most effective ISGs combating IAV infections. Further studies described the 
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presence of Mx proteins in almost all vertebrate species, where they exert diverse antiviral functions 
against a broad range of RNA as well as DNA viruses [146].  
Human cells express two types of Mx proteins: MxA present in the cytoplasm [147] and MxB 
localized to the cytoplasmic side of nuclear pores [148, 149]. Only MxA has been found to restrict IAV 
infection and will therefore be discussed in further detail [150-152]. Essentially two models have 
been described explaining the mechanism of MxA’s antiviral action. Based on crystal structures, one 
model suggests the assembly of MxA into oligomeric rings around incoming vRNPs, thereby leading 
to their disintegration [153]. However, this model is challenged by the fact that MxA had previously 
been observed to block IAV at a step after primary transcription [152]. The second model proposes 
an interaction of MxA dimers with de novo produced NP in the cytoplasm that restricts viral 
replication [154]. In agreement with both models, several studies identified the viral NP protein as 
determinant for MxA sensitivity, hence NP mutants evading MxA restriction have been described 
[155, 156]. 
 
1.5.4.2 PROTEIN KINASE R (PKR) 
PKR is a constitutively expressed but IFN-inducible serine/threonine kinase. Upon binding to dsRNA, 
5’-triphosphate ss-dsRNA (dsRNA with a single-stranded tail) or IAV vRNPs (most likely its pan-handle 
structure) [157, 158] PKR gets activated through autophosphorylation [159]. Activated PKR 
phosphorylates eukaryotic translation initiation factor 2α (EIF2α), thereby preventing translation 
initiation [160, 161]. As viruses depend on their host cell’s translation machinery, this strongly 
reduces viral replication [157]. In addition, activated PKR phosphorylates the inhibitor of NF-κB, 
thereby enabling NF-κB-dependent transcription of antiviral genes such as IFN-β [162]. PKR knockout 
mice showed increased susceptibility to IAV infection, establishing PKR as an important antiviral 
factor in vivo [163]. The fact that IAV evolved measures to counteract the activity of PKR further 
corroborates its in vivo relevance: NS1 has been shown to bind to PKR, thereby inhibiting its 
activation [164].  
 
1.5.4.3 2’,5’-OLIGOADENYLATE SYNTHETASE (OAS)/RNASEL 
The 2’,5’-oligoadenylate synthetase (OAS)/RNAseL system has been shown to lead to the 
degradation of cytoplasmic RNAs. Upon activation by dsRNA (or ssRNA forming a stem structure), 
OAS polymerizes ATP to 2’-5’ adenosine oligomers that activate the endoribonuclease RNAseL which 
cleaves cytoplasmic RNA [165, 166]. IAV has been shown to avert endonuclease restriction of its RNA 
by inhibiting OAS activation through the action of NS1. By binding to dsRNA, NS1 potentially 
sequesters cytoplasmic RNA that could otherwise activate OAS [167].  
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1.5.4.4 CHOLESTEROL-25-HYDROXYLASE (CH25H) 
CH25H, upregulated in macrophages and DCs upon IFN stimulation or TLR activation [168, 169], 
catalyzes the oxidation of cholesterol to 25-hydroxycholesterol (25HC) [170]. 25HC has been shown 
to inhibit a wide variety of enveloped viruses, such as IAV, HIV, VSV and HSV at the step of viral 
fusion [171, 172]. Increased 25HC concentrations seem to perturb cellular cholesterol homeostasis 
and lead to membrane modifications. Although the nature of these modifications has not been 
resolved completely, changes in membrane expansion, curvature or fluidity have been suggested and 
it was hypothesized that those perturbations of the host cell membrane interfered with the fusion 
process [171]. Interestingly, in addition to its direct antiviral role 25HC has also been shown to 
amplify inflammatory signals by increasing transcription of inflammatory cytokines. Intriguingly, 
deletion of the CH25H locus in mice was shown to be protective against IAV challenges lethal in wild 
type (wt) mice, most likely due to a decrease in inflammatory pathology [173].  
 
1.5.4.5 INTERFERON-INDUCED TRANSMEMBRANE PROTEINS (IFITMS) 
The first description of IFITMs dates back to the early 1980ies when they were identified as IFN-
stimulated genes in neuroblastoma cells [174]. Subsequent studies reported their upregulation in 
response to type I and type II IFNs [175]. However, for many years their antiviral potential remained 
undiscovered and their role was assigned to germ cell specification [176], transduction of anti-
proliferative and cell adhesion signals [177, 178] and immune cell signaling [179-181]. Two studies 
published in the late 1990ies and the early 2000s for the first time linked IFITMs to antiviral activity. 
IFITM1 was described to partially inhibit VSV [182] and IFITM3 was shown to impede hepatitis C virus 
RNA replication [183]. However, it was not until 2009 that the broad and potent antiviral potential of 
IFITM proteins was discovered in an siRNA screen and their antiviral activity against IAV, West Nile 
Virus and Dengue Virus demonstrated in tissue culture experiments [184]. Studies comparing IAV 
growth and pathology in IFITM3 wt vs. knockout mice observed accelerated disease progression, 
increased mortality and higher viral burdens in the absence of IFITM3 [185, 186]. Interestingly, 
IFITM3 knockout mice and mice having the entire IFITM locus deleted showed the same disease 
phenotype, suggesting that in mice protection against IAV is solely mediated by IFITM3 [185]. Further 
adding to the in vivo relevance of IFITM3, genome-wide association studies in humans hospitalized 
with a severe course of IAV infection during the swine flu pandemic in 2009 identified a single 
nucleotide polymorphism (SNP) in IFITM3 that leads to the generation of a splice acceptor site 
resulting in a truncated form of IFITM3 that lacks its first 21 amino acids (IFITM3 NΔ21). This 
shortened form of IFITM3 has been found less efficient in IAV restriction [186]. Authors analyzing 
different patient cohorts confirmed the association of this particular SNP in IFITM3 and the increased 
risk of a) acquiring IAV and b) suffering from a severe course of infection [187]. However, the 
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decrease in virus restriction capacity of IFITM3 NΔ21 could not be confirmed in another study that 
observed similar anti-IAV activities for IFITM3 and IFITM3 NΔ21 [188]. Nevertheless, many studies 
confirmed the importance of IFITMs, mostly IFITM3, as antiviral factors and demonstrated the IFITM-
mediated restriction of a vast variety of viruses, such as HIV [189, 190], VSV [191], Zika virus [192]), 
Ebola virus [193], and Rift Valley Fever virus [194]. 
 
IFITMs can be categorized into three subfamilies: immunity-related IFITMs (IFITM1-3 in humans), 
IFITM5 and IFITM10 [195]. Only immunity-related IFITMs have been shown to be induced by IFN 
[174, 175]. The presence of various immunity-related IFITMs next to each other on the same 
chromosome in most vertebrate species suggests that they arose through gene duplication. Together 
with the fact that they have been shown to be under positive selection and to protect against a 
variety of different viruses suggests that they are involved in the co-evolution of viruses and their 
hosts [195]. IFITM5 is exclusively restricted to bone cells, mostly osteoblasts, where it is involved in 
bone mineralization and maturation [196]. So far, no role could be assigned to IFITM10 but positive 
selection and gene duplication events in aquatic vertebrates suggests that IFITM10 might play a role 
in the adaptation to the aquatic environment [195]. 
 
IFITM proteins belong to the family of dispanins that comprises proteins harboring two 
transmembrane domains. Due to the presence of dispanins in several different phyla of bacteria one 
might speculate that they were acquired by eukaryotes through horizontal transmission [197]. IFITM 
proteins all follow the same architecture: a conserved CD225 middle domain is flanked by a variable 
N – and C – terminus, while the two transmembrane domains are located in the CD225 domain and 
at the transition between CD225 domain and C-terminus [195]. The transmembrane topology of 
IFITM proteins has been a matter of debate though. While some studies reported the accessibility of 
the N – and C – terminus by antibodies in unpermeabilized cells [179, 184, 191, 198] (Fig. 4a), others 
convincingly showed that the N-terminus is ubiquitylated [199] as well as phosphorylated [200], 
implying its accessibility by cytoplasmic enzymes (Fig. 5b/c). Introduction of a prenylation motif into 
the IFITM C-terminus allowed for its prenylation in the cytoplasm, proposing its cytoplasmic 
localization [199] (Fig. 5b). This study was challenged by another that reported the retention of 
IFITM3 in the ER, when an ER retention motif was added to the C-terminus [201] (Fig. 5a/b). The 
partial consensus of all these studies seems to be a type II transmembrane topology of IFITM 
proteins, as seen in Fig. 5c [202]. Nevertheless, the study describing a type II transmembrane 
topology for IFITM3 also reported that a minor fraction of IFITM3 had its N-terminus facing the ER 
lumen, suggesting that IFITMs could adopt different membrane topologies, thereby reconciling 
conflicting literature [201, 202].  
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Figure 5: IFITM protein membrane topology. (a) Predicted type III membrane topology with N – and C – 
termini facing the lumen of the ER. (b) Predicted intramembrane topology with the N – as well as the C – 
terminus facing the cytoplasm. (c) Predicted type II membrane topology with a cytoplasmic N – and a luminal C 
– terminus. Abbreviations: NTD, N-terminal domain; CTD, C-terminal domain; CIL, conserved intracellular loop; 
TM, transmembrane domain; IM, intramembrane domain [202] 
Subcellular localization of immunity-related IFITMs varies according to cell type. However, IFITM2 
and IFITM3 proteins have mainly been observed to localize to late endosomes and lysosomes in 
human and murine cells [185, 190, 193, 194, 203]. More precisely, IFITM3 has been shown to be 
expressed in alveolar type II pneumocytes in mice where it localizes to late endosomes and 
lysosomes. However, in murine ciliated respiratory epithelial cells, IFITM3 has been detected at the 
apical membrane [185]. Similarly, in activated murine CD8 T cells IFITM3 partly co-localized with the 
T cell receptor, while also early endosomal and lysosomal localization was observed [204]. IFITM1 
shows a subcellular localization distinct from IFITM2 and IFITM3 [194] and has been found mainly at 
the plasma membrane, although some studies also observed partial IFITM1 localization to late 
endosomal/lysosomal compartments [202]. 
 
IFITMs are subject to several post-translational modifications. They harbor three conserved cysteine 
residues shown to be S-palmitoylated, and this is associated with increased membrane affinity and 
antiviral activity [199, 205]. Furthermore, IFITM3 has been shown to be poly-ubiquitylated at several 
lysine residues by the cellular ubiquitin ligase NEDD4, which accelerates its turnover and negatively 
regulates its antiviral activity [199, 206]. Intriguingly, the IFN effector ISG15 has been reported to 
inhibit NEDD4 [207], suggesting that while IFITM3 is rapidly degraded in a non-infected cell to avoid 
cytotoxicity, it is upregulated and protected from degradation in an infected cell [206]. In addition, 
mono-methylation of a specific lysine residue in IFITM3 was reported to decrease its antiviral activity, 
but the underlying mechanism thereof remains to be discovered [208]. Interestingly, a recent study 
connected the IFITM3 SNP associated with an increased risk of acquiring and suffering from a severe 
course of IAV infection [186, 187] to a cellular phenotype. While IFITM3 resides primarily in late 
endosomes and lysosomes, IFITM3ΔN21 was shown to localize to the cell periphery [200]. Later, the 
same authors identified an N-terminal endocytosis motif in IFITM3 that is lacking in IFITM3ΔN21, 
which is responsible for the endosomal localization of IFITM3 [209]. Interestingly, phosphorylation of 
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a Tyrosine residue in this endocytosis motif has been shown to abrogate endosomal localization of 
IFITM3 [200]. Collectively, these studies indicate that post-translational modifications govern the 
subcellular localization and antiviral activity of IFITM proteins. 
 
Although the antiviral potential of IFITM proteins has been clearly established, their mechanism of 
antiviral action is still under debate. It was reported early on that IAV particles still bind to and are 
taken up in IFITM3-expressing cells, but their vRNPs are retained in the cytosol and do not reach the 
nucleus. Indeed, IAV seems to get trapped in late endosomes or lysosomes in IFITM3-expressing cells 
[203]. The exact step at which IFITMs block viral infection was then narrowed down to fusion by 
several studies. For fusion proteins activated at a low pH, lowering pH at 4 °C (cold arrested state) 
leads to so-called hemifusion (only the outer leaflets of two membranes mix). Fusion pore formation 
only takes place upon an increase in temperature (at neutral pH) or upon addition of chlorpromazine 
(CPZ). Intriguingly, while control cells displaying either the Jaagsiekte sheep retrovirus (JSRV) 
envelope glycoprotein (Env) or IAV HA on their surface proceeded to fusion upon raising the 
temperature or adding CPZ, IFITM1-expressing cells did not. This indicates that in IFITM1-expressing 
cells hemifusion might either not have occurred, or that IFITM1 inhibits the progression from 
hemifusion to fusion. Similarly, cell-cell fusion of HIV-1 Env- or IAV HA-expressing cells was reduced 
upon expression of IFITM1, 2 or 3 [198]. Further studies examining lipid mixing and fusion pore 
formation between labeled IAV particles and the endosomal membrane observed that lipid mixing 
occurred in the presence or absence of IFITM3, while fusion pore formation was inhibited when 
IFITM3 was present [210]. Potentially explaining the inhibitory activity of IFITMs on membrane 
fusion, two independent studies provided convincing evidence that the presence of IFITMs in a 
membrane decreases its fluidity [198, 211]. The first study made use of Laurdan, a hydrophobic 
fluorescent probe that shows differential emission depending on the polarity of its environment. 
Laurdan is used to report on the amount of water permeating a membrane, which serves as correlate 
of lipid packing [212]. Membranes of cells expressing IFITM1, 2 or 3 were shown to be more ordered 
compared to control cells [198]. The second study employed fluorescence recovery after 
photobleaching (FRAP) to study membrane fluidity in control cells or cells expressing IFITM1. The 
delayed return of fluorescence in IFITM1-expressing cells compared to control cells indicated a 
decrease in membrane fluidity upon presence of IFITM1 in cellular membranes [211]. In support of 
this notion, the antifungal compound amphotericinB known to increase membrane fluidity has been 
reported to abrogate IFITM3-mediated inhibition of IAV [211]. Similarly, some studies hypothesized 
that IFITMs might confer positive curvature to membranes which would also hamper the fusion 
process [198, 211, 213], especially if IFITMs formed multimers, as reported by one study [213]. 
However, while one report showed the abrogation of the IFITM-mediated block on fusion by the 
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addition of oleic acid (OA) which induces negative membrane curvature [198], no effect of OA 
addition could be observed in another [211]. Yeast two-hybrid studies looking for cellular interaction 
partners of IFITMs discovered that IFITM1, 2 and 3 can interact with the vesicle-membrane protein-
associated protein A (VAPA), thereby disturbing its association with oxysterol-binding protein (OSBP). 
VAPA-OSBP is involved in the regulation of cholesterol homeostasis and disruption of this interaction 
by IFITM3 was hypothesized to be the cause for the late-endosomal accumulation of cholesterol in 
IFITM-expressing cells [214]. An increase in cholesterol decreases membrane fluidity, matching 
previous observations that the presence of IFITMs in membranes increases their lipid order [198, 
211]. Accordingly, overexpression of VAPA alleviated the inhibition IFITM3 exerted on IAV [211, 214]. 
However, although the intracellular accumulation of cholesterol upon overexpression of IFITM1 or 
IFITM3 was independently observed [211, 214], several studies challenged the hypothesis of 
cholesterol being the determinant of IFITM-mediated restriction of viral entry. These studies did not 
observe any influence on IFITM-mediated viral restriction upon modulation of cellular cholesterol 
levels [210, 211].  
 
Recently, IFITMs have also been appreciated for their functions during late stages of viral infection, in 
addition to their role in inhibiting incoming viruses. Two studies reported the incorporation of IFITMs 
into budding HIV-1 virions which was found to be associated with a decrease in virion fusion capacity 
[215, 216]. The authors of both studies speculated that an increase in positive membrane curvature 
and a decrease in membrane fluidity upon IFITM incorporation into the viral membrane would 
negatively affect fusion of viral and host cell membranes, comparable to what has been hypothesized 
for IFITMs residing in target cell membranes. They also observed a dose-dependency between the 
amount of IFITM incorporated and the reduction in virion entry capacity [215, 216]. In contrast, other 
investigators while also reporting IFITM incorporation into HIV-1 virions could not confirm such dose-
dependent effects. Rather, they observed a direct interaction between IFITM2 or 3 and Env. This 
interaction resulted in an impairment of Env processing and incorporation, leading to the production 
of virions with a decreased entry capacity [217]. 
 
Although we gained a deep understanding on how IFITM expression levels and localization are 
regulated and inhibit viral entry, several key questions remain unanswered. For example, it needs to 
be elucidated why some viruses are inhibited by IFITMs while others are not. For many viruses it has 
been shown that they are specifically inhibited by IFITMs localized to their fusion site, as IAV for 
example is blocked by IFITM3 localized to late endosomes. In contrast, the arenavirus Machupo virus 
that follows the same cellular entry route as IAV (clathrin-mediated endocytosis followed by pH-
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induced fusion in late endosomes) is not affected by IFITM3 [184, 218, 219]. This cannot be explained 
by the current models for the antiviral mechanism of IFITM proteins. 
 
 
1.6 AIMS OF THE PHD THESIS 
IFITM proteins have been described as potent antiviral factors inhibiting the entry of a variety of 
different viruses, such as IAV and HIV. While human and mouse IFITMs have been studied in great 
detail, very little was known about IFITM proteins and their activity in other species at the time this 
PhD project was started. Since IAV is a zoonotic virus we aimed to address whether hosts other than 
humans, such as birds or pigs, are also protected from infection by IFITM proteins. Thus, the first part 
of this PhD project was dedicated to  
 
the characterization of swine IFITM proteins in terms of localization, IFN-inducibility and antiviral 
potential against IAV. 
 
In the second part of this PhD thesis we aimed to elucidate the antiviral mechanism of action of 
IFITM proteins in more detail. In particular we investigated 
 
the contribution of IFITM proteins to the cellular antiviral defense during late stages of the IAV life 
cycle. 
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Swine Interferon-Inducible Transmembrane Proteins Potently Inhibit
Influenza A Virus Replication
Caroline Lanz,a,b Emilio Yángüez,a Dario Andenmatten,a Silke Stertza
Institute of Medical Virology, University of Zurich, Zurich, Switzerlanda; Life Sciences Zurich Graduate School, ETH and University of Zurich, Zurich, Switzerlandb
Human interferon-inducible transmembrane proteins (IFITMs) were identified as restriction factors of influenza A virus (IAV).
Given the important role of pigs in the zoonotic cycle of IAV, we cloned swine IFITMs (swIFITMs) and found two IFITM1-like
proteins, one homologue of IFITM2, and a homologue of IFITM3.We show that swIFITM2 and swIFITM3 localize to endosomes
and display potent antiviral activities. Knockdown of swIFITMs strongly reduced virus inhibition by interferon, establishing the
swIFITMs as potent restriction factors in porcine cells.
The interferon-inducible transmembrane proteins (IFITMs)were identified as potent inhibitors of different viruses, in-
cluding influenza A virus (IAV), West Nile virus, severe acute
respiratory syndrome (SARS) coronavirus, and others (1–5). In
particular, human and mouse IFITM3 have been studied with
regard to their antiviral potential but also their mechanisms of
viral restriction. ifitm3 knockout mice showed accelerated disease
progression and higher morbidity and mortality upon IAV infec-
tion than wild-typemice (6).Moreover, it was found that humans
with a single nucleotide polymorphism in the ifitm3 gene have a
significantly higher risk for a severe course of IAV infection (6, 7).
The antiviral mechanism of the IFITMs is not yet fully under-
stood, but it has become clear that viral fusion is targeted by these
proteins (8–11). While we have a good understanding of the an-
tiviral potential of human andmouse IFITMs,much less is known
about the activities of IFITMs in other species. Given the impor-
tant role of pigs in the zoonotic cycle of IAV,we aimed to elucidate
the antiviral potential of swine IFITMs (swIFITMs).
We cloned swIFITMs from cDNA obtained from interferon
(IFN)-stimulated pig cells according to sequences deposited in the
NCBI database. We were able to amplify the porcine homologues
of human IFITM1, IFITM2, and IFITM3. For IFITM1, two por-
cine homologues that differ in their N and C termini, named
swIFITM1a and -1b, were found. Swine IFITM5 could not be
amplified out of cDNA and was thus synthesized. The amino acid
alignment of the IFITMs from humans, pigs, and chickens shows
that the IFITMs display certain features that are conserved across
all three species, such as the two transmembrane domains, the
palmitoylation sites at positions 73 and 74, or the ubiquitination
sites at positions 85, 90, and 106 (Fig. 1A) (12–14). Moreover,
swine and human IFITM2 and IFITM3 share an N-terminal ex-
tension of about 20 amino acids that contains the endocytosis
motif YEML,which the IFITM1s of both species lack (Fig. 1A) (15,
16). This alignment suggests that the swine IFITMs may have an-
tiviral properties similar to those of their human counterparts.
The induction of human IFITM1 to -3 upon IFN stimulation
or virus infection is well established (1, 17). While Miller et al.
showed that in pig swIFITMs are induced in tracheobronchial
lymph nodes upon infection (18), a direct induction of swIFITMs
upon IFN treatment has not been established to date. We thus
tested the inducibility of swIFITMs upon IFN stimulation or IAV
infection in porcine cell lines. We stimulated porcine NpTr, PK-
15, or NSK cells with universal IFN (1,000 U/ml) for 24 h or
infected them with A/WSN/33 (WSN) (multiplicity of infection
[MOI], 0.01) for 24 h or 48 h (19). Reverse transcription-quanti-
tative PCR (RT-qPCR) with specific primers for the individual
swIFITMs (primer sequences are available upon request) re-
vealed a pronounced upregulation of swIFITM1a, swIFITM1b,
swIFITM2, and swIFITM3 upon IFN stimulation or infection in
NSK as well as PK-15 cells (Fig. 1B and C). In contrast, swIFITM
transcripts were induced less than 3-fold in NpTr cells (Fig. 1D).
Moreover, when we treated NpTr cells with strong inducers of the
IFN response, such as IAV lacking NS1, poly(I·C), or a prepara-
tion of Sendai virus that contains large amounts of defective in-
terfering particles, we detected only low levels of swIFITM induc-
tion (Fig. 1E). This was not limited to swIFITMs; also swine MX1
and swine OAS, both known to be upregulated by IFN, displayed
only low levels of induction. This suggests that the NpTr cells are
not able tomount a strong IFN response. Despite these differences
in the levels of induction of the swIFITMs, all three cell lines were
permissive for robust replication of IAV (Fig. 1F). Expression of
swIFITM5 could not be detected in any of the cell lines (data not
shown). These results suggest that like their human counterparts,
swIFITM1 to -3 constitute a first line of defense against viral in-
fections.
Next, we analyzed the subcellular localization of the swIFITMs.
We transiently transfected human A549, swine NpTr, or swine
NSK cells with constructs encoding Flag-tagged human or swine
IFITMs. IFITMs were stained using an antibody against the Flag
tag, while late endosomes were marked using an antibody recog-
nizing lysobisphosphatidic acid (LBPA) (20). Confocal micros-
copy revealed that the subcellular localization of porcine IFITMs
is similar to that of their human homologues, with swIFITM1a
and -1b localizing predominantly to the plasma membrane but
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FIG 1 Amino acid alignment of human, swine, and chicken IFITMs and induction of swine IFITMs upon IFN stimulation or virus infection. (A) Amino acid
alignment of human, swine, and chicken IFITM1, IFITM2, IFITM3, and IFITM5. Functional motifs and domains are highlighted with colored boxes. Abbrevi-
ations: hu, human; sw, swine; ch, chicken; TM, transmembrane domain. (B toD) Induction of swIFITM expression by IFN or IAV infection. NSK (B), PK15 (C),
or NpTr (D) porcine cells were infected with A/WSN/33 at an MOI of 0.01 or treated with universal IFN (1,000 U/ml) for 24 h. At the indicated times
posttreatment, total mRNA was extracted and used to perform RT-qPCR using specific oligonucleotides for the different swIFITMs or swMX1 as a positive
control. Fold changes were calculated according to the Pfaffl method (24) using swine GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA as a
reference. A representative experiment from two biological replicates, each performed in triplicate, is shown, with error bars representing the 95% confidence interval.
Statistical significance between results for IFN-treated or IAV-infected cells and control untreated cells was assessed by an unpaired two-tailed Student t test
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with swIFITM2 and -3 accumulating in late endosomes. This is
illustrated by their colocalization with the late endosomal marker
LBPA in representative images (Fig. 2A) and the quantification of
colocalization from 8 to 12 cells per construct and cell line (Fig.
2B). Of note, human and swine IFITM2 displayed the highest
degrees of colocalizationwith LBPA. The observed localization for
the human IFITMs is in agreement with that found in previous
reports for overexpressed but also for endogenous human IFITMs,
validating our approach (8). Moreover, the endosomal localiza-
tion of human and swine IFITM2 and -3 confirms the importance
of the endocytosis motif in the N terminus for pronounced local-
ization to endosomes (15, 16). When we analyzed the localization
of the swIFITMs during IAV infection, we did not detect changes
in their intracellular distribution from that in uninfected cells
(Fig. 2C).
To evaluate the antiviral potential of swIFITMs, we performed
an IAV reporter assay with cells transiently transfected with the
different swIFITMs. The reporter plasmid encodes luciferase in
complementary reverse orientation flanked by IAV noncoding re-
gions, preceded by a human or swine pPolI promoter for use in
human or porcine cells, respectively. This assay provides the ad-
vantage that only reporter activity from transfected cells is mea-
sured, enabling us to assess the impact of the different IFITMs on
IAV in a transient-transfection system. The construct for human
cells has been used before (21), and for porcine cells, we adapted a
construct described previously by introducing three mutations at
positions 3, 5, and 8 in the promoter region (22, 23). After trans-
fection with the reporter plasmid plus the IFITM-encoding plas-
mid indicated in the figures, we used IAV A/WSN/33 to infect
HEK293-T cells at an MOI of 0.1 and NpTr cells at an MOI of 1
and measured luciferase production 24 h postinfection (p.i.). We
observed that swIFITMs show a dose-dependent restriction of
IAV in HEK293-T cells, with swIFITM2 and -3 being the most
antivirally active and their activities being comparable to that of
human IFITM3 (huIFITM3) (Fig. 3A). However, it should also be
noted that swIFITM2, swIFITM3, and huIFITM3 were expressed
to higher levels than the other IFITMs, which is in line with the
dose dependency of restriction. We then confirmed the antiviral
activities of swIFITMs in porcine cells, with swIFITM2 showing
the most potent restriction of IAV (Fig. 3B). These data from the
transient-transfection assay suggest that the swIFITMs possess an-
tiviral activities.
In order to corroborate these findings, we generated stable cell
lines overexpressing the different swIFITMs in the background of
the porcine NpTr and NSK cells by lentiviral transduction. Cells
were subcloned until more than 99% of cells were positive for
expression. To test the antiviral activities of overexpressed
swIFITMs, we infected the cell lines with either the human strain
A/Hong Kong/68 (MOI, 1) or the swine isolate A/swine/Zurich/
25/06 (MOI, 1). At 48 h p.i., supernatants were harvested and viral
titers determined by plaque assay. Expression of the swIFITMs
reduced titers of IAV in the NpTr cell lines; swIFITM2 was the
most potent, with reducing titers of around 1,000-fold (Fig. 3C
andD). It should be noted that we were not able to generate stable
NpTr cell lines expressing high levels of swIFITM3 and -5 (Fig.
3E), whichmight contribute to the reduced potency of swIFITM3
compared to that of swIFITM2. In the NSK cell lines, we also
observed potent inhibition of IAV replication upon expression of
the different swIFITMs, except for swIFITM1b (Fig. 3F and G).
Again, swIFITM2 displayed the most potent antiviral activity. As
in theNpTr cells, we were not able to generate cell lines expressing
high levels of swIFITM3 or swIFITM5. These data suggest that
high expression levels of these two swIFITMs are notwell tolerated
in porcine cells. The differences in expression levels make a direct
comparison of the antiviral activities difficult since we observed in
the transient-transfection assay of 293T cells that higher expres-
sion levels lead to better inhibition of IAV. However, when we
compared swIFITM2 to swIFTIM1a or -1b, expression levels were
similar, but swIFITM2was themost active.Moreover, swIFITM3,
despite being expressed at much lower levels than swIFITM1a or
-1b, had comparable activity.We therefore suggest that swIFITM2
and swIFITM3, which localize predominantly to late endosomes,
display the strongest antiviral potential.
Since the assays described above were performed with over-
expressed swIFITMs, we next assessed whether endogenous
swIFITMs also reduce viral replication. To this aim, porcine NSK
cells were transfected with two different small interfering RNAs
(siRNAs) targeting swIFITMs (siIFITM1, siIFITM2), a positive-
control siRNA against the viral nucleoprotein (NP), or a negative-
control nontargeting siRNA. At 36 h posttransfection, cells were
either mock treated or treated with universal type I IFN (1,000
U/ml). At 12 h posttreatment, cells were infected with IAV
A/WSN/33 (MOI, 0.0001), supernatants were harvested at 24 h
p.i., and virus titers were determined by plaque assay. In the ab-
sence of IFN, knockdown of swIFITM had no effect on virus titers
(Fig. 4A, gray bars). However, in IFN-treated cells, viral titers were
increased by 10-fold when swIFITMs were downregulated (Fig.
4A, black bars). To confirm that knockdown by siRNA was suc-
cessful, wemeasuredmRNA levels for the different swIFITMs and
swMX1 in parallel samples and found that both siRNAs designed
to target all IFN-induced swIFITMs potently downregulated their
expression but that swMX1 as a control IFN-stimulated gene was
not affected (Fig. 4B and C). Knockdown of swIFITMs by the two
different siRNAs was further confirmed at the level of protein.
Since detection of endogenous porcine swIFITMs was unsuccess-
ful using available antibodies for human IFITMs, we tested the
siRNAs in the NSK cell lines overexpressing swIFITMs and con-
firmed knockdown (Fig. 4D). Downregulation of viral NP levels
by the NP-specific siRNAwas also confirmed byWestern blotting
(Fig. 4E). These data show that swIFITMs constitute an important
part of the IFN response against IAV in porcine cells and confirm
our results obtained with overexpression of swIFITMs.
In summary, we show that swIFITM1 to -3 are upregulated by
type I IFN and IAV infection in porcine PK-15 and NSK cells.
(*, P 0.05). (E) NpTr cells were transfected with poly(I·C) or infected with A/PR/8/34NS1 (NS1) or Sendai virus (SeV) for 24 h. Total mRNAwas extracted
and used to perform RT-qPCR with specific oligonucleotides. Fold changes were calculated according to the Pfaffl method using swGAPDH mRNA as a
reference. The results of a representative experiment are shown, with error bars representing the 95% confidence intervals. Statistical significance between
poly(I·C)-treated or infected cells and control untreated cells was assessed by an unpaired two-tailed Student t test (*, P 0.05). (F) IAV replication in porcine
cell lines. NSK, PK-15, and NpTr cells were infected with A/WSN/33 as described for panels B to D, and viral titers in the supernatant at 24/48 h p.i. were
determined by plaque assay. The dashed line indicates the limit of detection.
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FIG 2 Localization of human and swine IFITMs in human and porcine cells. (A) Representative confocal images of humanA549 cells (a to g), porcineNpTr cells
(h to k), or porcine NSK cells (l to o) transfected with Flag-tagged human or porcine IFITM-encoding constructs are shown. IFITMs were stained using an
antibody against the Flag epitope (red) late endosomes using an antibody against the late endosomal marker LBPA (green), and cell nuclei were marked using
DAPI (4=,6-diamidino-2-phenylindole) (blue). Cells were imaged using a 63 objective and a magnification of3 (scale bar 10 m). (B) Colocalization of
IFITMs with the late endosomemarker LBPA was quantified. Horizontal bars represent the mean of the Pearson’s correlation coefficient (Rr) calculated for 8 to
12 cells using ImageJ, with error bars marking the 95% confidence interval. Statistical significance of increased colocalization for the indicated IFITM construct
compared to that of huIFITM1 or swIFITM1a, respectively, was assessed by an unpaired two-tailed Student t test (*, P 0.05; **, P 0.01; ***, P 0.001; ****,
P 0.0001). (C) Representative confocal images of NSK cells transfected with Flag-tagged porcine IFITM-encoding constructs and infected with A/WSN/33 at
anMOI of 5 are shown. IFITMswere stained using an antibody against the Flag epitope (red), infectionwas controlled using an antibody against IAVNP (green),
and cell nuclei were marked using DAPI (blue). Cells were imaged using a 63 objective and a magnification of3 (scale bar 10 m).
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FIG 3 Expression of swIFITMs potently inhibits IAV. (A and B) Transient-transfection assays. HEK293-T (A) and NpTr (B) cells were transfected with an IAV-
dependentfirefly luciferase reporter construct and increasing amounts of plasmids encodingFlag-tagged swine IFITMs.At 24hposttransfection, cellswere infectedwith
A/WSN/33 at an MOI of 0.1 (A) or 1 (B). At 24 h p.i., cells were lysed and firefly luciferase activity was measured. Data were normalized to luciferase activity in cells
transfected with an inactive Mx1 mutant (neg con), while murine Mx1 and human IFITM3 served as positive controls (pos con). Mean values from three biological
replicates, each performed in triplicate, are shown,with error bars representing standard deviations. Statistical significance between cells transfectedwith swIFITMs and
cells expressing the negative control was assessed by an unpaired two-tailed Student t test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). Expression levels
of swine IFITMs were confirmed byWestern blotting and quantified usingMulti Gauge software; expression levels in relation to human IFITM3 expression are given
below theWestern blots. (C toH) Stable cell lines expressing swIFITMs.NpTr (C,D) orNSK (F,G) cells stably overexpressing Flag-tagged swIFITMswere infectedwith
A/Hong Kong/68 (MOI, 1) (C, F) or A/swine/Zurich/25/06 (MOI, 1) (D, G). At 48 h p.i., supernatants were harvested and virus titers determined via plaque assay on
MDCK cells. Mean values from three replicates are shown, with error bars representing standard deviations. Statistical significance between titers from cells expressing
swIFITMs and cells transduced with the empty vector (con) was assessed by an unpaired two-tailed Student t test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P
0.0001).Thedashed lines indicate the limit ofdetection.Expression levels of swIFITMswere confirmedbyWesternblotting andquantifiedbyMultiGauge software, and
expression levels relative to the strongest band are given below theWestern blots (E, H).
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FIG 4 Endogenous swIFITMs contribute to the antiviral activity of IFN in porcine cells. (A) NSK cells were transfected with two siRNAs targeting swIFITMs (#1
and #2) or the viral nucleoprotein (NP) or with a nontargeting control siRNA. At 36 h posttransfection, cells were either left untreated or treated with universal
type I IFN (1,000 U/ml). At 12 h posttreatment, cells were infected with A/WSN/33 (MOI, 0.0001) and supernatants were harvested at 24 h p.i. Viral titers were
determined by plaque assay. Mean values with standard deviations from three replicates are shown. The dashed line indicates the limit of detection. (B, C) A
parallel set of samples was siRNA transfected andmock or interferon treated as described above. At 48 h posttransfection, cells were harvested andmRNA levels
of the different swIFITMs and swMX1 were determined by RT-qPCR. Fold changes were calculated according to the Pfaffl method using swGAPDHmRNA as
a reference. Mean values with the 95% confidence interval from three replicates are shown. Statistical significance between NP- or swIFITM-silenced cells and
cells transfected with the nontargeting siRNAwas assessed by an unpaired two-tailed Student t test (*, P 0.05). (D) Stable NSK cells expressing swIFITMs were
transfected with either an siRNA targeting swIFITMs or a nontargeting control siRNA (con). At 48 h posttransfection, cells were lysed and the amount of
Flag-tagged swIFITMswas assessed byWestern blotting. Results for two different swIFITM-specific siRNAs (#1 and #2) are shown. (E)NSK cells were transfected
with either an siRNA targeting IAVNP or a nontargeting control siRNA (con). At 36 h posttransfection, cells were treatedwith universal type I IFN (1,000U/ml),
and 12 h posttreatment, cells were infectedwith A/WSN/33 (MOI, 0.0001) as described for panel A. At 24 h p.i., cells were lysed andNP levels assessed byWestern
blotting.
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While swIFITM1a and -1b displayed prominent plasma mem-
brane localization, swIFITM2and -3were found to colocalizewith
a marker for late endosomes. Overexpression of swIFITMs re-
sulted in reduced influenza virus reporter activity and reduced
viral titers. Although different expression levels of the swIFITMs
make a direct comparison of the antiviral potencies difficult, the
data suggest that swIFITM2 and swIFITM3 display the strongest
antiviral activities. Importantly, we also show that endogenous
swIFITMs constitute a large part of the antiviral activity of IFN in
porcine cells. In future studies, it will be interesting to characterize
the IFITMs from different swine breeds for their antiviral poten-
tial and thereby help to select pig breeds with increased resistance
to IAV infections.
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Abstract 
Interferon-inducible transmembrane proteins (IFITMs) are potent antiviral factors that inhibit a 
variety of different viruses, such as influenza A virus (IAV), HIV and West Nile virus, at the step of viral 
entry. Recently, IFITMs have been reported to be incorporated into HIV virions upon budding, 
thereby decreasing virion infectivity. Here we provide evidence that IFITM3 also incorporates into 
IAV VLPs and IAV virions. IAV VLPs were compromised in their infectivity when produced in IFITM3-
expressing cells and this effect was alleviated in a dose-dependent manner by increasing HA 
concentrations in producer cells. In contrast, IAV virions were not negatively affected in their 
infectivity upon presence of IFITM3 in producer cells, however, they showed increased neutralization 
sensitivity to HA-directed antibodies, potentially compromising them in an in vivo situation. In 
summary, we establish a role for IFITM3 in late stages of the IAV life cycle. 
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Introduction 
Interferon-inducible transmembrane proteins (IFITMs) have been described as potent antiviral 
factors blocking the entry step of many different viruses, such as influenza A virus (IAV), HIV, West 
Nile virus, Dengue virus, Zika virus, VSV and others [1-8]. Although basally expressed, IFITMs 1, 2 and 
3 are highly upregulated upon stimulation of cells with type I or type II interferon (IFN) [1, 9, 10]. 
Importantly, IFITM3 has been shown to constitute a major part of the interferon response against 
IAV in human cells [1].  
Nevertheless, how exactly IFITMs inhibit viral infections is still under debate. Current literature 
agrees that cellular membranes show increased positive curvature and decreased membrane fluidity 
upon incorporation of IFITMs, offering a convincing explanation to why IFITMs block the fusion 
between cellular and viral membranes [11-13]. In addition to their biophysical properties, IFITMs also 
rely on an appropriate subcellular localization to exert their antiviral function. The presence of an N-
terminal endocytosis motif in IFITM2 and 3 responsible for endo-lysosomal targeting of those 
proteins has been proven necessary for antiviral activity [3, 14, 15]. In addition, post-translational 
palmitoylation of conserved cysteine residues was found to be required for the clustering of IFITM3 
in membranes, which in turn is a prerequisite for antiviral activity [16]  
While the inhibitory effect on viral entry exerted by IFITMs residing in target cells has been studied in 
great detail, knowledge on the consequences of IFITM presence in virus-producing cells is still 
accumulating. Compton [17] and Tartour [18] and colleagues were the first to show that IFITM 
proteins get incorporated into budding HIV-1 virions, which they find to be associated with a 
decrease in virion entry capacity. Consequently, knockdown of endogenous IFITMs increased the 
infectivity [18] and the cell-to-cell spread [17] of HIV-1 virions. Both authors favour the hypothesis of 
biophysical properties (positive membrane curvature, decreased membrane fluidity) imposed on the 
viral membrane through IFITM incorporation to explain the reduction in virion infectivity. 
Intriguingly, in recent studies performed by Yu and colleagues [19] incorporation of IFITMs into HIV-1 
virions was also demonstrated but the authors did not observe a correlation between the amount of 
IFITM incorporated and the reduction in virion entry capacity. They observed that IFITM2 and 3 can 
interact with Env, the envelope glycoprotein of HIV-1, impair its processing and decrease its 
incorporation into newly produced virions, thereby leading to a decrease in virion infectivity.  
Knowing that IAV is strongly inhibited by IFITMs at the entry step [1, 3, 4, 12, 20-22], we wondered 
whether similar to the situation in HIV-1, IFITMs also target later stages of the IAV life cycle. To 
address this question we assessed the infectivity of HIV virus-like particles (VLPs) pseudotyped with 
IAV HA and NA and IAV VLPs that were produced in the presence or absence of IFITM3 and found a 
significant decrease in VLP infectivity when IFITM3 was present in producer cells. We present 
experimental evidence that IFITM3 acts on the IAV envelope glycoprotein HA in producer cells by 
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demonstrating that IFITM3-induced negative effects on VLP infectivity are alleviated in a dose-
dependent manner by increasing HA concentrations. In contrast, when comparing IAV grown on 
IFITM3-overexpressing cells versus control cells infectivity remained unaffected by the presence of 
IFITM3. However, we observed an increase in neutralization sensitivity of virus grown in the presence 
of IFITM3, which we hypothesize to be detrimental for the virus in an in vivo situation. Therefore, our 
study establishes a role for IFITM3 in late stages of IAV infection. 
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Materials and Methods 
Cells 
HEK293-T, A549, TZM-bl and MDCKII cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal calf serum (FCS; Thermo Fisher Scienific) and 
penicillin-streptomycin (100 U/mL; Thermo Fisher Scientific). IFITM3 was amplified from 
cDNA extracted from IFN-α-stimulated A549 cells using the following primers: 5’-
gacagaattcatggactacaaagacgatgacg-ataaaaatcacactgtccaaa-3’ (forward) and 5’- 
gacactcgagctatccataggcctggaa-3’ (reverse). After restriction by EcoRI and XhoI, the IFITM3 
PCR product was ligated into the pLVX-IRES-Puromycin vector plasmid (Clontech) to yield 
pLVX-IFITM3. A549 and TZM-bl cells stably overexpressing IFITM3 were generated by 
lentiviral transduction with particles harboring pLVX-IFITM3. IFITM3-expressing cells were 
subcloned and cultured in the presence of 1 μg/mL puromycin (Thermo Fisher Scientific). 
 
HIV-based virus-like particle production, purification and infection 
HIV-VLPs pseudotyped with either the HIV-1 JRFL, IAV A/WSN/33 or VSV envelope glycoproteins 
were generated by transfecting HEK293-T cells with pNLLuc-AM [23], envelope expression – and Flag-
IFITM3 expression plasmids (or the empty vector pCAGGS for the production of VLPs in the absence 
of IFITM3) at the ratio of 9 : 1.5 : 1. Polyethyleneimine (PEI; Sigma-Aldrich) was used as transfection 
reagent (2 μg PEI/μg DNA). VLPs were harvested 72 hours post-transfection and their concentration 
was determined by an in-house p24 ELISA. A549 or TZM-bl cells seeded into 96-well plates were 
infected with VLPs at an equivalent of 3 ng p24/well for 90 minutes in the presence of DEAE-dextran 
(150 μg/mL; Sigma-Aldrich), before the inoculum was removed and replaced by DMEM 
supplemented with 10% FCS and penicillin-streptomycin (100 U/mL). VLP infectivity was measured 
48 hours post-infection by quantifying firefly luciferase activity using the ONE-Glo Luciferase Assay 
System (Promega) according to the manufacturer’s protocol. For analysis of VLPs by Western Blot 
VLPs were purified as follows: After an initial centrifugation at 1500 x g for 5 minutes to remove 
cellular debris, VLP-containing supernatant was filtered through a 0.45 μm filter. To achieve a more 
stringent removal of cellular debris, supernatant was ultracentrifuged at 10’000 rpm at 4 °C for 20 
minutes, before ultracentrifugation of VLPs through a 20% (w/v) sucrose cushion in NTE buffer 
(100mM NaCl, 10 mM Tris-HCl pH7.5, 1mM EDTA pH8) at 25’000 rpm for 90 minutes. Supernatant 
was then decanted and the VLP pellet dissolved in Optimem at 4 °C O/N (Gibco). 
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IAV-based virus like particle (BlaM1 VLP) production, normalization and infection 
VLPs harboring β-lactamase-M1 (BlaM1) fusion proteins were produced essentially as described by 
Tscherne & Garcìa-Sastre [24]. Briefly, HEK293-T cells seeded into poly-L-lysine-coated (Sigma-
Aldrich) 6-well plates were transfected in Optimem (Gibco) with 2.5 μg BlaM1, 500 ng pCAGGS-WSN-
HA, 1.125 µg pCAGGS-WSN-NA, 250 ng pCAGGS-WSN-M2 and 300 ng pCAGGS-IFITM3/pCAGGS-eV 
per well using ViaFect (Promega) as transfection reagent (2.5 µl ViaFect/µg DNA). Medium was 
exchanged 8 hours post-transfection. VLPs were harvested 72 hours after transfection and treated 
with 6 μg/mL TPCK-trypsin (Sigma-Aldrich) for efficient HA cleavage. For infection of MDCKII cells 
BlaM1 VLP input was normalized by Western Blotting for BlaM1 using the mouse monoclonal anti-
IAV M1 (HB-64, American Type Culture Center) antibody. Four hours post-infection cells were 
harvested by trypsinization and incubated with the fluorigenic substrate CCF2-AM (ThermoFisher 
Scientific). CCF2-AM taken up into the cells is cleaved into CCF2 by cellular esterases and is thereby 
trapped inside the cell. CCF2 is cleaved by β-lactamase brought in by the infecting VLPs, thereby 
shifting its emission wavelength from 520 nm to 447 nm when excited at 409 nm. Cells were 
analysed on a FACSVerse System (BD) and dead cells excluded by a live/dead staining (LIVE/DEAD 
Fixable Near-IR Dead Cell Stain Kit, ThermoFisher Scientific).  
 
Influenza A virus infections 
All cells were washed with PBS prior to infection. IAV A/WSN/33 was diluted to an MOI of 0.1 or 1 in 
PBS supplemented with 2 mM Mg2+, 1 mM Ca2+, 0.3% BSA and 1% penicillin-streptomycin (infection 
PBS; PBSi). Infection was performed at 37 °C for 1 hour. Thereafter, virus inoculum was removed and 
cells washed with PBS, before DMEM containing 20 mM HEPES, 0.3 % BSA and 1% penicillin-
streptomycin (post-infection DMEM; p.i.DMEM) was added to the cells. Virus was grown in the 
presence of 1 μg/mL TPCK trypsin (Sigma-Aldrich) for 48 hours.  
To normalize viral input in subsequent infectivity assays, qPCR on the viral M segment was 
performed. Viral RNA was extracted using the QIAamp Viral RNA Kit (Qiagen) and cDNA synthesized 
by the SuperScript III Reverse Transcriptase (ThermoFisher Scientific) using random primers 
(Promega). qPCR was performed using EvaGreen Master Mix for qPCR (Biotium) with the following 
primers: 5’-GCAGCAGAGGCCATGGATATTG-3’ (forward) and 5’-TTTGCTGCAATGACGAGAGGATC-3’ 
(reverse). Virus grown on control or IFITM3-expressing A549 cells was prediluted according to qPCR 
results for all infectivity assays. 
Virus infectivity was measured in an IAV reporter assay described by Hoffmann and colleagues [25]. 
Briefly, HEK293-T cells seeded into 96-well plates were transfected with 20 ng/well of an IAV reporter 
plasmid encoding firefly luciferase in complementary reverse orientation, flanked by IAV non-coding 
regions, thus mimicking an IAV segment. 24 h post-transfection, cells were infected with A/WSN/33 
  Chapter 3 
49 
 
at an MOI of 0.3. 24 h post-infection luciferase activity was measured using the ONE-Glo luciferase 
assay substrate (Promega) according to manufacturer’s protocols.  
To assess IFITM incorporation into IAV by Western Blotting virus was purified as described for HIV 
VLPs and subjected to Western Blotting as described below.  
 
Western Blotting 
To prepare cell extracts, cells were lysed in 1X Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 10% 
glycerol, 2% SDS, 100 mM dithiothreitol, 0.02% bromophenol blue). Viruses and VLPs were mixed 
with 5X Laemmli buffer to obtain 1X Laemmli buffer lysates. Samples were run on SDS-PAGE gels and 
blotted onto nitrocellulose membranes (Hybond ECL, GE healthcare). All stainings were performed in 
tris-buffered saline mixed with 0.5 % Tween-20 (Sigma-Aldrich) and 3 % powdered milk. The 
following antibodies were used: mouse monoclonal anti-Flag (clone M2, Sigma-Aldrich), rabbit 
polyclonal anti-IFITM3 (Proteintech), mouse monoclonal anti-β-actin (Santa Cruz Biotechnology), 
mouse monoclonal anti-HIV-1 p24 (ab9071, abcam), mouse monoclonal anti-IAV M1 (HB-64, 
American Type Culture Center), rabbit polyclonal anti-NP (a kind gift of A. Nieto), mouse monoclonal 
anti-A/WSN/33 HA (clone H15-B9-22 [26], Wistar) and rabbit polyclonal anti-A/WSN/33 (a kind gift of 
B. Hale). Secondary antibody staining was performed using near-infrared fluorescent secondary 
antibodies (Li-Cor) and images were acquired on an Odissey Fc imaging system. Western Blot signal 
intensities were quantified using the Image StudioTM software (Li-Cor). 
 
 
Transmission Electron Microscopy of immunogold-labeled viral particles 
Viral particles were purified as described above. Carbon-coated nickel grids were glow-discharged 
before purified viral particle solution was applied. Samples were fixed with 4% paraformaldehyde in 
0.1 M HEPES for 7 min. After one short wash in PBS, samples were permeabilized with 0.5% Triton-X-
100 in PBS for 1 min and washed again three times in PBS. Free aldehydes were quenched with 0.15 
% glycine in PBS. To prevent unspecific antibody binding samples were blocked in 1% bovine serum 
albumin (BSA, Merck) in PBS. Primary antibody staining was performed using rabbit polyclonal anti-
IFITM3 antibody (Proteintech) diluted in 1% BSA in PBS. Samples were washed three times in 1% BSA 
in PBS, before secondary antibody staining was performed using a goat anti-mouse IgG Gold antibody 
(Sigma-Aldrich) at on optical density of 0.15. After secondary antibody staining, samples were 
washed in PBS and fixed in 4% paraformaldehyde in 0.1M HEPES, before being negatively stained 
with 1% uranyl acetate and imaged in a Philips CM100 transmission electron microscope operated at 
100 kV. 
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Results 
IFITM3 present in VLP-producing cells restricts the entry capacity of HIV VLPs pseudotyped with 
IAV HA/NA and HIV envelopes 
While several papers elucidated the role of IFITM3 incorporation into HIV particles and its negative 
effect on virion infectivity [17-19], nothing is known about similar mechanisms occuring in the IAV 
life cycle. First, we employed a virus-like particle (VLP) system based on HIV to address whether the 
presence of IFITM3 in VLP producer cells also leads to a reduction in entry capacity of VLPs 
pseudotyped with IAV HA/NA, similar to what has been described for VLPs pseudotyped with HIV 
Env. We transfected HEK293-T cells with pNL-LucAM, a plasmid encoding the HIV strain NL4-3 
genome but having its envelope gene replaced by a luciferase gene, together with plasmids encoding 
either the HIV-1 JRFL, IAV A/WSN/33 or VSV envelope genes (or the empty vector plasmid pCAGGS 
for the no envelope control) in the presence or absence of Flag-IFITM3 (Fig. 1A). VLPs produced 
under these conditions were purified and analysed for IFITM3 incorporation by Western Blotting for 
the Flag epitope (Fig. 1B). All VLPs exhibited a strong Flag signal, suggesting that IFITM3 was 
incorporated into VLPs and that incorporation occurred envelope-independently, as previously 
described by Compton and colleagues [17]. VLPs produced in the absence of IFITM3 were 
subsequently tested for their infectivity in A549 human lung epithelial cells (Fig. 1C) or HeLa TZM 
cells (Fig. 1D) engineered to express the HIV-1 receptors CD4 and CCR5. While A549 cells could be 
infected with IAV HA/NA – as well as VSV-G - pseudotyped VLPs, TZM cells could be infected with 
VLPs pseudotyped with HIV – as well as VSV envelopes. We then compared the infectivity of VLPs 
produced in the presence of IFITM3 with VLPs produced in the absence of IFITM3. Interestingly, VLPs 
pseudotyped with IAV HA/NA or HIV-1 Env were restricted in their infectivity when produced in cells 
expressing IFITM3, while VSV-G pseudotyped VLPs did not seem to be affected in their infectivity by 
the presence of IFITM3 in producer cells (Fig. 1E&F).  
 
IFITM3 blocks VLP infectivity at the level of the producer cell as well as the target cell for IAV and 
HIV-1 but not for VSV in an HIV-based VLP system 
Next, we were interested to see whether we can see differential effects of IFITM3 presence in 
producer and target cells in the context of IAV, HIV-1 and VSV VLP infection. To this end we 
generated A549 and HeLa TZM cells stably overexpressing IFITM3 that were subsequently infected 
with VLPs produced in the presence or in the absence of IFITM3. 
In accordance with previous studies we observed a significant reduction in IAV VLP entry into A549 
cells upon IFITM3 expression in those cells (Fig. 2A). Interestingly, this reduction is comparable to the 
decrease in VLP infectivity we see upon presence of IFITM3 in VLP producer cells. Similar results were 
obtained for HIV-1 VLPs infecting TZM cells (Fig. 2B). VSV VLPs were significantly inhibited in their 
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infectivity when IFITM3 was expressed in target cells, while presence of IFITM3 in VLP producer cells 
did not negatively affect their infectivity (Fig. 2C).  
 
IFITM3 in VLP-producing cells restricts the entry capacity of IAV VLPs 
In a next step we aimed to see whether the observed decrease in VLP infectivity could be reproduced 
in an IAV-based VLP system. To this end we made use of a β-lactamase-M1 VLP assay described by 
Tscherne and Garcìa-Sastre [24]. Briefly, HEK293-T cells were transfected with plasmids encoding a β-
lactamase-M1 fusion protein, IAV HA, NA and M2 (in the presence or in the absence of IFITM3) to 
produce IAV VLPs. The entry efficiency of these VLPs can be assessed by loading of infected target 
cells with CCF2, a fluorigenic substrate that shifts in emission upon cleavage by β-lactamase carried 
into the cell by the infecting VLP (Fig. 3A). When we then tested those VLPs for their infectivity in 
MDCKII cells we observed a marked reduction in entry efficiency for VLPs produced in the presence 
of IFITM3. The left panel of Fig. 3B shows one representative experiment, while the right panel 
summarizes the results of three independently performed experiments. 
To check whether IFITM3 also incorporates into IAV VLPs, VLPs produced in the absence or in the 
presence of IFITM3 were purified and subjected to Western Blot analysis. A distinct Flag-IFITM3 band 
could be detected in VLPs produced in IFITM3-expressing cells, suggesting that similar to HIV VLPs, 
IFITM3 also incorporates into IAV VLPs (Fig. 3C). Interestingly, we observed a decrease in VLP HA 
signal upon presence of IFITM3 in VLP producer cells (Fig. 3C). This decrease in envelope 
glycoproteins was also detected in HIV VLPs pseudotyped with HIV Env or IAV HA/NA (Suppl. Fig. 1). 
We thus conclude that IFITM3 can also be incorporated into IAV-based VLPs and that the presence of 
IFITM3 in IAV VLP producer cells leads to an entry deficiency of those VLPs, possibly through a 
reduction in HA abundance on the VLP’s surface. 
 
HA but not NA outcompetes IFITM3 in VLP producing cells 
Given that IFITM3 reduced the abundance of HA in IAV VLPs we wondered whether IFITM3 already 
decreased the amount of HA present in producer cells. To this end, 293-T cells were co-transfected 
with increasing amounts of a Flag-IFITM3 encoding plasmid and a constant amount of a plasmid 
coding for HA. However, Western Blot analysis revealed that total HA levels were only marginally 
reduced upon an increase in IFITM3 expression (Fig. 4A). Next, we tested whether IAV HA or NA 
could outcompete the negative effect of IFITM3 on VLP infectivity when present in producer cells. To 
this end, IAV VLPs were produced in 293-T cells transfected with a constant amount of IFITM3 or the 
empty vector pCAGGS as negative control in the presence of increasing amounts of HA or NA. 
Western Blot analysis of these VLPs confirmed that transfecting increasing amounts of HA led to 
increased amounts of HA present in the VLPs. Furthermore, we could confirm our previous 
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observation that IFITM3 reduced the amount of HA incorporated into VLPs. Interestingly, in the 
presence of IFITM3, the increase in HA incorporation was paralleled by a decrease in IFITM3 
incorporation (Fig. 4B). We then normalized the input amount of VLPs via Western Blot for BlaM1 
and infected MDCKII cells. Intriguingly, while the negative effect of IFITM3 on VLP infectivity was 
alleviated in a dose-dependent manner by an increase in HA, increasing the amount of NA did not 
affect VLP infectivity (Fig. 4C).  
 
IFITM3 incorporates into wild type IAV and increases its neutralization sensitivity 
Our experiments described so far showed that IFITM3 present in producer cells negatively affected 
infectivity of HIV- and IAV-based VLPs pseudotyped with IAV glycoproteins. To address whether this 
was also true for IAV virions we infected A549 cells stably overexpressing IFITM3 with a high MOI of 
A/WSN/33 for 72 hours. When purifying and analysing viral supernatants via Western Blot we 
observed an enrichment of IFITM3 in supernatants from infected cells compared to mock-infected 
cells, suggesting that IFITM3 incorporated into viral particles (Fig. 5A). To corroborate our finding on 
IFITM3 incorporation into IAV, viral supernatants were subjected to transmission electron 
microscopy, where incorporation of IFITM3 into IAV virions was confirmed (Fig. 5B). Furthermore, HA 
levels were found to be reduced in virus cultured on IFITM3-overexpressing cells compared to virus 
grown on control cells (Fig. 5A), similar to what has been observed for HIV and IAV VLPs (Suppl. Fig. 
1, Fig. 3C, Fig. 4C). To compare the infectivity of virus grown on IFITM3-overexpressing vs. control 
cells we performed a luciferase IAV mini-genome reporter assay or plaque assays using qPCR-
normalized viral inputs. In contrast to the results obtained with VLPs, IAV grown on IFITM3-
overexpressing cells was not reduced in its infectivity compared to virus cultured on control cells (Fig. 
5C). In an attempt to explain these conflicting results and remembering that sensitivity to IFITM3 
depended on the levels of HA present in VLP producer cells (Fig. 4C) we analysed producer cell 
lysates from IAV, HIV VLP and IAV VLP samples (Fig. 5D). Interestingly, ratios between IFITM3 and HA 
signal intensities varied between the different samples, with HIV and IAV VLPs showing higher 
IFITM3:HA ratios than IAV, correlating with their respective IFITM3 sensitivities.  
Finally, our observation that IFITM3 decreased the amount of HA incorporated into virions (Fig. 5A) 
would predict that virus grown on IFITM3-expressing cells would be more susceptible to 
neutralization by HA-directed antibodies than virus grown on control cells. To test this, viral 
supernatants from either control or IFITM3-expressing cells normalized by qRT-PCR were pre-
incubated with a dilution series of a monoclonal anti-A/WSN/33 HA antibody, before being used to 
infect MDCKII cells. Indeed, when treated with the same amount of anti-HA antibody, virus grown in 
the absence of IFITM3 was more infectious than virus grown in the presence of IFITM3, as depicted in 
Fig. 5E.  
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In summary, we show that IAV VLPs are decreased in their infectivity upon IFITM3 presence in VLP 
producer cells and that sensitivity to IFITM3 is alleviated in a dose-dependent manner by an increase 
in producer cells’ HA but not NA concentration. Furthermore, we observed a reduction in HA 
incorporation into IAV as well as IAV VLPs when IFITM3 was expressed in producer cells, which was 
corroborated by the finding that IAV cultured on IFITM3-expressing cells showed increased HA-
neutralization sensitivity. Together these findings suggest a role for IFITM3 in late stages of the IAV 
life cycle.  
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Discussion 
IFITM proteins are potent interferon-induced antiviral factors blocking IAV as well as many other 
viruses at the step of viral entry [1-5, 7]. Intriguingly, recent studies [17], [18] [19] established an 
additional antiviral function of IFITMs exerted against HIV-1 much later in the viral life cycle. 
Compton [17] and Tartour [18] and colleagues reported the incorporation of IFITMs into nascent 
virions, which they found to be associated with a decrease in virus infectivity. Although not ruling out 
a potential effect of IFITMs on the envelope glycoprotein (Env), the authors hypothesized that the 
biophysical properties imposed on membranes through IFITM incorporation (positive curvature, 
decreased membrane fluidity), account for the decrease in virion fusogenicity. In contrast, Yu [19] 
and colleagues observed an interaction between IFITM3 and Env that led to the impairment of Env 
processing and incorporation. Interestingly, although they also reported IFITM incorporation into 
budding virions, they saw no correlation between the amount of IFITM incorporation and decrease in 
fusion capacity.  
Here, we show that HIV-based VLPs pseudotyped with IAV HA and NA, HIV-1 Env or VSV-G 
incorporated IFITM3 (Fig. 1B). Of note, IFITM3 was also detected in no Env VLP controls, confirming 
that IFITM3 incorporation occurs Env-independently, as has been shown previously [17]. In 
agreement with current literature [17-19] we observed a reduction in entry capacity of VLPs 
pseudotyped with HIV-1 Env upon presence of IFITM3 in producer cells. Intriguingly, the same was 
found to hold true for VLPs displaying IAV HA and NA. We did not observe a negative effect on the 
entry capacity of VSV-G pseudotyped VLPs upon presence of IFITM3 in VLP producer cells, 
disagreeing with findings published earlier [17, 18]. This might be explained by differences in VSV-G 
to IFITM3 ratios in VLP producer cells between the different studies. Furthermore, we observed that 
IFITM3 blocked VLP infectivity at the level of the producer as well as the target cell for HIV Env and 
IAV HA/NA, but not VSV-G pseudotyped VLPs. We therefore suggest that for certain viral envelopes, 
IFITM3 in producer cells contributes to IFITM3’s antiviral activity to a similar extent as IFITM3 
expressed in target cells. While VLPs pseudotyped with VSV-G were not inhibited by IFITM3 
expressed in producer cells (Fig. 1E-F & Fig. 2C), IFITM3 in target cells potently blocked VSV-G VLP 
infection, in line with previous observations that VSV was inhibited by IFITMs [7].  
We also report IFITM3 incorporation into β-lactamse-M1 (BlaM1) IAV VLPs and show that the 
presence of IFITM3 in producer cells significantly decreased the entry capacity of those VLPs (Fig. 3B). 
We therefore conclude that IFITM incorporation into VLPs is not specific to the HIV-based, but also 
true for an IAV-based VLP system. Interestingly, we observed a reduction in IAV VLP HA upon 
presence of IFITM3 in VLP producer cells (Fig. 3C) which could negatively affect and thus explain the 
reduction in VLP infectivity. Since IFITM3 was not found to reduce cellular HA levels (Fig. 4A) we 
hypothesize that the reduction in VLP HA is either brought about by competition between IFITM3 
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and HA in cellular membranes or by a direct interaction between IFITM3 and HA that negatively 
regulates HA incorporation. We then determined whether an increase in HA in VLP producer cells 
would outcompete IFITM3. By testing the entry efficiency of BlaM1 VLPs produced in the presence of 
increasing amounts of HA or NA we show that HA indeed is targeted either directly or indirectly by 
IFITM3, since increasing amounts of HA titrated out the negative effect of IFITM3 on VLP infectivity in 
a dose-dependent manner, while increasing the amount of NA did not have any consequences on 
VLP infectivity (Fig. 4C). Interestingly, we again observed a decrease in HA signal in VLPs produced in 
IFITM3-expressing cells compared to VLPs produced in control cells. At the same time, an increase in 
HA incorporation was paralleled by a decrease in VLP-associated IFITM3 (Fig. 4B), suggesting that HA 
and IFITM3 might indeed compete for incorporation into cellular membranes. 
When analyzing supernatants from either mock-treated or IAV-infected IFITM3-expressing cells we 
observed an enrichment of IFITM3 in the supernatant of infected cells (Fig. 5A), suggesting that 
IFITM3 was incorporated into nascent virions. However, as it had been observed previously [19, 27], 
we also detected a significant amount of IFITM3 in the supernatant of uninfected cells (Fig. 5A), most 
likely stemming from IFITM3-containing exosomes that potentially confound our conclusions. To 
clarify whether or not IFITM3 incorporates into IAV we subjected our samples to transmission 
electron microscopy and could indeed demonstrate that IFITM3 was present in the membrane of IAV 
cultured on IFITM3-expressing cells (Fig. 5B). Furthermore, we detected a decrease in the HA0 : M1 
ratio in IAV grown on IFITM3-overexpressing cells compared to virus grown on control cells (Fig. 5A), 
reminiscent of the reduction in HA upon presence of IFITM3 in HIV and IAV VLP producer cells (Fig. 
3C, 4C, S1) and similar to observations described for HIV-1 [19]. Surprisingly, neither IFITM3 
incorporation, nor a reduction in HA, negatively affected IAV infectivity, as assessed by plaque assay 
or a luciferase reporter mini-genome assay (Fig. 5C). One might speculate that the IFITM3:HA ratio in 
producer cells might be decisive in whether or not IFITM3 negatively imprints on virus/VLP infectivity 
(Fig. 5D). In fact, IFITM3:HA ratios in producer cells determined for the experiments reported in this 
study correlated with the negative effect IFITM3 exerted on virus/VLP infectivity. Although we did 
not observe a negative effect on IAV infectivity upon IFITM3 presence in infected cells, we wondered 
whether the observed reduction in HA might render the virus more neutralization-sensitive. By 
incubating virus grown on either control or IFITM3-overexpressing cells (normalized by qRT-PCR) with 
different dilutions of an HA-directed antibody prior to infection, we could indeed show that IAV 
cultured on IFITM3-overexpressing cells was more neutralization-sensitive. It is tempting to speculate 
that this would compromise a virus in an in vivo situation.  
Sensing an invading virus or stimulated by IFN, a cell expresses a broad variety of interferon-
stimulated genes (ISGs) that act as antiviral factors [28]. IFITM3 has been described as one of the 
most potent ISGs in human cells and mice. Brass and colleagues [1] demonstrated that IFITM3 
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constitutes approx. 50 % of the IFN-α and –γ response in cultured human cells and Bailey and 
colleagues [22] reported faster disease progression, higher viral loads and a higher mortality in mice 
lacking the ifitm3 locus. While the role of IFITM3 in blocking the entry step of various viruses has 
been extensively studied [1, 2, 4-8, 11, 20, 29], the notion that IFITM3 also acts on later stages of the 
viral life cycle and incorporates into budding virions [17-19] is rather new. However, other ISGs have 
been reported to be packaged into viruses before. A prime example is APOBEC3G, a cytidine 
deaminase that damages the viral genome through hypermutation by inducing G to A mutations in 
the viral cDNA [30-32]. In the constant arms race between virus and host, HIV-1 evolved 
countermeasures to antagonize APOBEC3G-mediated restriction. Its accessory protein Vif has been 
found to promote proteasomal degradation of APOBEC3G, as well as its exclusion from budding 
virions [33]. In contrast to Vif, no viral antagonist counteracting IFITM has been discovered to date. 
While two studies [19, 34] reported the emergence of HIV strains partly refractory to IFITM-mediated 
inhibition, resistance was attributed to truncations in Vpu and mutations in Env in both cases. 
Interestingly, a recent publication identified the HIV V3 loop as determinant for IFITM3 susceptibility 
in the context of IFITM incorporation [35]. This is in line with previous observations that HIV 
susceptibility to IFITMs is modulated by co-receptor usage [36], which is known to be steered by the 
V3 loop [37]. 
We found no direct correlation between IFITM incorporation and reduction in viral/VLP infectivity 
but rather suggest that the interplay between IFITMs and envelope glycoproteins determines 
virus/VLP sensitivity to IFITM incorporation. For IAV it is tempting to speculate that on an 
evolutionary scale, IFITMs might drive the virus towards higher levels of HA incorporation. Further 
studies will be needed to elucidate whether other viruses have evolved different strategies to 
circumvent IFITM restriction.  
In summary, we show that IAV is targeted by IFITM3 not only at the step of viral entry but also at late 
stages of infection. By blocking viruses at different steps of their life cycle IFITM3 broadens its 
antiviral potential and likely impedes the development of viral resistances.  
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Figure legends 
Figure 1: IFITM3 present in VLP-producing cells restricts the entry capacity of HIV VLPs 
pseudotyped with IAV and HIV envelopes. A) Schematic depiction of HIV VLP generation. 293-T cells 
were co-transfected with pNL-LucAM (NL4-3 genome having the envelope gene replaced by the 
firefly luciferase gene), plasmids encoding the HIV JRFL, IAV A/WSN/33 or VSV envelope gene and 
either Flag-IFITM3 or the empty vector pCAGGS. VLPs were harvested 72 h post-transfection. B) VLPs 
described in A) were purified and concentrated by ultracentrifugation through a 20% sucrose 
cushion, normalized via p24 ELISA and analyzed by Western Blot. Membrane was probed with anti-
Flag and anti-p24 antibodies. C) Fold luciferase activity (compared to the empty vector control) in 
A549 cells infected for 48h with VLPs produced in the absence of IFITM3. D) Fold luciferase activity 
(compared to the empty vector control) in TZM cells infected for 48h with VLPs produced in the 
absence of IFITM3. E) % infectivity (compared to infectivity of VLPs produced in the absence of 
IFITM3) of VLPs pseudotyped with IAV or VSV envelopes in the presence or absence of IFITM3 in 
A549 cells. F) % infectivity (compared to infectivity of VLPs produced in the absence of IFITM3) of 
VLPs pseudotyped with HIV or VSV envelopes in the presence or absence of IFITM3 in TZM cells. C-F) 
Mean values from three biological replicates, each performed in triplicate, are shown, with error bars 
representing standard deviations. E-F) Statistical significance was assessed by a paired two-tailed 
Student t test (**, P<0.01; ****, P<0.0001). 
 
Figure 2: IFITM3 blocks VLP infectivity at the level of the producer cell as well as the target cell for 
IAV and HIV-1 but not for VSV in an HIV-based VLP system. A-C) % infectivity of HIV VLPs 
pseudotyped with IAV A/WSN/33 HA and NA (A), HIV JRFL Env (B) or VSV-G (C) produced in the 
presence or absence of IFITM3. VLPs pseudotyped with IAV Envs were used to infect A549 cells (A), 
while VLPs harboring HIV-1 or VSV Envs were used to infect TZM cells (B-C) that were either IFITM3-
negative  (-IFITM3) or IFITM3-positive (+IFITM3). Data were normalized to infectivity in control cells 
infected with VLPs produced in the absence of IFITM3. Mean values from three biological replicates, 
each performed in triplicate, are shown, with error bars representing standard deviations. Statistical 
significance was assessed by a paired two-tailed Student t test (*, P<0.05; **, P<0.01), comparing the 
infectivity in the different conditions to infectivity of VLPs produced in the absence of IFITMs 
infecting IFITM3-negative cells. 
 
Figure 3: IFITM3 in VLP-producing cells restricts the entry capacity of IAV VLPs. A) Schematic 
depiction of the β-lactamase-M1 (BlaM1) VLP assay. VLPs harboring a β-lactamase-M1 fusion protein 
and displaying A/WSN/33 HA and NA at their surface are used to infect target cells. Upon cellular 
entry, β-lactamase is released into the cytoplasm and cleaves the fluorigenic substrate CCF2 which 
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shifts in emission upon cleavage (modified from [38]). B) BlaM1 VLPs produced in the presence 
(+IFITM3) or absence (-IFITM3) of IFITM3 normalized via Western Blot were used to infect MDCKII 
cells. VLP entry-positive (harboring cleaved CCF2) and -negative (harboring uncleaved CCF2) cells 
were assessed by FACS. Left: Depiction of density plots of one representative experiment. The 
percentage of entry-positive cells is indicated. Right: Infectivity of +IFITM3 VLPs normalized to –
IFITM3 VLPs. Bars represent the mean of three biological replicates, with the error bar representing 
standard deviation. Statistical significance was assessed by a paired two-tailed Student t test (**, 
P<0.01), comparing the infectivity of +IFITM3 VLPs to the infectivity of –IFITM3 VLPs. C) VLPs 
described in B) were purified and concentrated by ultracentrifugation through a 20% sucrose cushion 
before being analyzed by Western Blot. Membrane was stained using a polyclonal antibody against 
A/WSN/33 proteins and an antibody against IFITM3. Expression levels of HA2 normalized to BlaM1 
levels are given below the HA2 WB.  
 
Figure 4: HA but not NA outcompetes IFITM3 in VLP producing cells. A) 293-T cells were co-
transfected with pCAGGS-HA and increasing amounts of pCAGGS-Flag-IFITM3. Whole cell lysates 
were analyzed by Western Blot and membrane was stained for HA, Flag and actin. Expression levels 
of HA0 in relation to the strongest band are given below the HA0 WB. The asterisk marks the 
condition used for the production of VLPs with the lowest amount of HA in B). B) VLPs produced in 
the presence or absence of IFITM3 and increasing amounts of HA were analyzed by Western Blot. 
Membrane was stained using a polyclonal antibody against A/WSN/33 proteins and a Flag antibody. 
HA2 and IFITM3 band intensities were normalized to BlaM1. Expression levels of HA2 and IFITM3 in 
relation to the strongest band are given below the respective WBs. C) BlaM1 VLPs produced in 
IFITM3-positive (+I3) or IFITM3-negative (-I3) cells in the presence of increasing amounts of HA (left) 
or NA (right) were used to infect MDCKII cells. For each condition, bars representing the percentage 
of entry-positive cells from +I3 VLP infection normalized to entry-positive cells from –I3 VLP infection 
are shown. 
 
Figure 5: IFITM3 incorporates into wt IAV and increases its neutralization sensitivity. A) A549 
control or IFITM3-overexpressing cells were infected with A/WSN/33 at MOI 1 for 72h. Supernatants 
were purified and concentrated by ultracentrifugation through a 20% sucrose cushion before being 
lysed and analyzed by Western Blot. Membrane was probed for HA, M1 and IFITM3. HA0 band 
intensities were normalized to M1 and the expression level of HA0 in relation to the stronger band is 
given below the respective WB. B) Virus described in A) was purified and concentrated by 
ultracentrifugation through a 20% sucrose cushion. For Immuno-EM studies virus was fixed and 
immunogold labeled using a polyclonal anti-IFITM3 antibody. Scale bar: 100 nm C) Left: Virus 
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described in A) was normalized via RT-qPCR and its infectious titer determined via plaque assay on 
MDCK cells. Right: 293-T cells were transfected with a reporter plasmid encoding firefly luciferase in 
complementary reverse orientation flanked by IAV noncoding regions, thus mimicking a viral genome 
segment. Cells were subsequently infected with virus described in A) that was normalized via RT-
qPCR. Luciferase signal was measured 48h p.i. D) IFITM3-positive (+I3) and -negative (-I3) virus, HIV 
VLP and IAV VLP producer cells were lysed and analyzed by Western Blot. Membrane was stained 
using a polyclonal antibody against A/WSN/33 proteins and antibodies against Flag and GAPDH. Flag-
IFITM3 : HA ratios for each condition are given below the Western Blot. E) Virus described in A) was 
normalized via RT-qPCR and incubated with different dilutions of a monoclonal anti-A/WSN/33 HA 
antibody before being used for infecting MDCKII cells. Cells were fixed 4h p.i. and infectivity was 
assessed by microscopy-based quantification of NP-positive cells. 
 
Supplemental Figure 1: HIV VLPs pseudotyped with HIV or IAV Envs show decreased glycoprotein 
levels when produced in IFITM3-overexpressing cells. A) VLPs described in Fig. 1B) were analyzed by 
Western Blot. Membrane was stained using antibodies against p24, Flag, HIV Env, VSV-G and 
A/WSN/33 proteins. The panel on the left depicts one representative Western Blot, while the right 
panel shows the quantification of normalized Env signal intensities from Western Blots performed 
using three independent VLP batches. Statistical significance was assessed by a paired two-tailed 
Student t test (*, p<0.05).  
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DISCUSSION 
4.1 IFITM PROTEINS ARE POTENT INHIBITORS OF VIRAL ENTRY 
Immunity-related IFITMs (IFITM1-3 in humans) are interferon-stimulated genes (ISGs) that inhibit a 
broad variety of different viruses from entering their target cells [202]. It is likely that the multiple 
IFITM gene duplication events that occurred in various species [195, 197] allowed for the functional 
diversification of these proteins from their roles in germ cell homing and maturation [220-222] to 
functions in antiviral immunity. Among immunity-related IFITMs, further gene duplications enabled 
the evolution of an array of IFITM proteins differing in their motifs responsible for subcellular 
localization, thereby facilitating their distribution to the different sites within a cell where viral fusion 
occurs [223]. Although IFITM proteins have been shown to increase positive membrane curvature 
[198, 211, 213] and to decrease membrane fluidity [198, 211] which was shown to interfere with the 
viral fusion process, the precise mechanism of IFITM’s antiviral activity has not been resolved to date. 
While IFITMs have been reported to inhibit the entry of a variety of enveloped viruses, such as HIV 
[189, 190], VSV [191], IAV [184, 186] and Zika virus [192] and of one non-enveloped virus (reovirus) 
[224], several viruses have been shown to be refractory to IFITM-mediated restriction or to even 
profit from their activity. Human cytomegalovirus (HCMV) assembly takes place at the vAC, a 
perinuclear structure induced by the virus that has been shown to require IFITMs for their correct 
formation, possibly through the IFITM-mediated cholesterol accumulation in late 
endosomes/lysosomes [214, 225]. In contrast to HCMV that was shown to require IFITMs for virion 
assembly, human coronavirus OC43 (HCoV-OC43), a virus that enters host cells via endocytosis and 
whose envelope protein undergoes pH-dependent activation, was reported to benefit from IFITMs 
upon entry. While IFITMs did not influence envelope protein activation, the authors suggested 
IFITM’s influence on membrane rigidity was required for the enhancement of HCoV-OC43 entry, 
since IFITM mutants unable to homo – or heterodimerize failed to enhance viral entry, a phenotype 
copied by the addition of amphotericin B to the cells [226], a compound that has been reported to 
increase membrane fluidity [214]. However, considering that IFITMs are also involved in cellular 
signaling processes [178, 180, 227] and that the IFITM’s C-terminus was found to be critical for HCoV-
OC443 entry enhancement [226], one might also speculate that HCoV-OC43 interacts with the IFITM 
C-terminus (which according to the most current membrane topology models is assumed to be 
accessible by virus binding to the cell surface [202]) to induce a signaling cascade that ultimately 
facilitates the process of viral fusion.  
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Furthermore, IFITMs have been reported to be ineffective in inhibiting certain viruses even though 
they do enter cells via endocytosis and require a low pH for envelope-mediated entry, such as human 
papillomavirus, adenovirus, cytomegalovirus [228] and arenaviruses [184]. Further studies on IFITM’s 
antiviral mechanism might provide insight into potential strategies employed by these viruses to 
circumvent IFITM-mediated restriction, as for example the usage of alternative entry pathways to 
bypass IFITM-rich cellular compartments. 
 
 
4.2 IDENTIFICATION OF SWINE INTERFERON-INDUCIBLE TRANSMEMBRANE PROTEINS AS 
POTENT INHIBITORS OF INFLUENZA A VIRUS REPLICATION 
Due to the presence of α2,3 – as well as α2,6-linked sialic acid residues in the porcine trachea, pigs 
can be simultaneously infected with IAV strains from avian and human origin. They are thus 
hypothesized to play an important role in zoonotic transmission of IAV by facilitating genetic 
reassortment between IAV strains of different origin [88]. Wondering whether similar to humans 
[186] and mice [185] pigs are also protected from IAV infection by IFITM proteins we cloned the 
porcine homologues of human IFITM1-3 from IFN-stimulated porcine cells. IFITM proteins have been 
described to be very conserved in terms of protein motifs [197] and indeed, swIFITM protein 
sequences were very similar to their human counterparts, with the respective endocytosis motifs, 
transmembrane domains, intracellular loops, ubiquitination and palmitoylation sites highly 
conserved (Chapter 2, Fig. 1A). Interestingly, pigs were found to express two homologues of IFITM1, 
named swIFITM1a and swIFITM1b. All porcine IFITM homologues were found to be induced upon IAV 
infection or stimulation with universal IFN in porcine newborn swine kidney (NSK) and porcine kidney 
15 (PK15) cells, except for swIFITM1a, which in NSK cells was only induced upon IFN-stimulation 
(Chapter 2, Fig. 1B-C). These observations matched results published in a previous study that 
reported the upregulation of swIFITMs in tracheobronchial lymph nodes in pigs infected with IAV 
[229]. Newborn pig trachea (NPTr) cells were found to be unresponsive to IFN-stimulation (Chapter 
2, Fig. 1D). Like their human homologues, swIFITM2 and 3 localized to late endosomes and lysosomes 
and swIFITM1a was found predominantly at the plasma membrane in human as well as porcine cells. 
Intriguingly, while swIFITM1b localized almost exclusively to the plasma membrane in human A549 
cells, some degree of colocalization with late endosomal/lysosomal markers was observed in porcine 
cells (Chapter 2, Fig.2). SwIFITM1a and 1b differ only slightly in their N – and C – termini. However, it 
was shown for human IFITM1 that the C-terminus regulates part of its anti-HIV-1 activity by 
modulating subcellular localization [230]. Since this has not been linked to a sequence motif so far, it 
might be interesting to swap the C-termini of swIFITM1a and swIFITM1b to check whether 
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differences in their localization and antiviral potential are solely attributable to their C-termini. 
Furthermore, testing the inhibitory potential of swIFITM1a and swIFITM1b against retroviruses and 
comparing them to human IFITM1 may provide additional insights into motifs or residues required 
for viral restriction.  
While IFITM1’s antiviral activity is steered by the protein’s C-terminus, human IFITM3 harbors an N-
terminal endocytosis motif responsible for its localization to late endosomes/ lysosomes [29], which 
has been shown to be required for anti IAV activity. Interestingly, N-terminal deletion mutants 
localize predominantly to the plasma membrane where they efficiently inhibit HIV-1. Compton and 
colleagues [223] showed in primates that IFITM3 underwent recurrent duplications (marmosets 
harbor as many as 25 copies of IFITM3), thereby allowing for the introduction of various mutations 
that have been shown to affect protein turn over and localization and ultimately antiviral potential 
against different viruses. Along those lines, it might be interesting to test porcine viruses and 
compare their sensitivities to swIFITM1a versus swIFITM1b. 
In our study, we already assessed the antiviral potential of the different swIFITMs in human as well as 
porcine cells in an IAV mini-genome reporter assay [231] and a dose-dependent restriction capacity 
was observed for all swIFITMs tested, with swIFITM2 and 3 being the most antivirally active IFITMs, 
comparable to huIFITM3 which was used as positive control (Chapter 2, Fig. 3A-B). With the 
exception of swIFITM1b and swIFITM5 expressed in NSK cells, swIFITMs overexpressed in porcine 
NSK and NPTr cells significantly reduced IAV replication. In contrast to human or mouse Mx proteins 
that are highly active against avian IAV but lost their antiviral potential against human IAV strains 
[232], no differential sensitivity to swIFITMs was detected when comparing IAV strains of human and 
porcine origin (Chapter 2, Fig. 3C-H). Later, this observation was extended to avian IAV strains 
(Master thesis Eva Müller, unpublished data). This is in line with the hypothesis that IFITMs block 
fusion between the viral and the host cell membrane [198, 210] by decreasing membrane fluidity and 
increasing positive membrane curvature [198, 211, 213], which makes the occurrence of resistances 
rather unlikely, since all IAV strains, independent of their origin, eventually need to fuse with host 
cell membranes. Altering their HA to increase their optimal fusion pH might enable IAVs to fuse in an 
early endosome, thereby (partly) evading IFITM3. However, such viruses would likely suffer from 
decreased environmental stability [233, 234]. In contrast, Mx targets the viral NP protein that evades 
antiviral restriction by undergoing adaptive mutations [156].  
Interestingly, the cell type-specific restriction capacity observed for swIFITM1b correlated with its 
subcellular localization. swIFITM1b showed higher co-localization with late endosomes/lysosomes in 
NPTr cells compared to NSK cells (Chapter 2, Fig. 2A-B), suggesting that in NPTr cells swIFITM1b was 
present at the site of IAV fusion, thereby increasing its antiviral capacity. However, this interpretation 
fails to explain why swIFITM1a which is expressed predominantly at the plasma membrane still 
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restricted IAV growth in both porcine cell lines. It is possible that in addition to blocking the fusion 
between viral and host cell membranes, IFITMs expressed at the plasma membrane also decrease 
endocytosis, which would result in a reduction in viral infection. To my knowledge, this has never 
been tested. Furthermore, since IFITMs have been reported to decrease membrane fluidity [198, 
211], they might interfere with receptor tyrosine kinase (RTK) signaling in lipid rafts induced upon 
binding of IAV to the cell, which has been hypothesized to be required for IAV uptake [54].  
Due to variations in IFITM expression levels in the different overexpressing cell lines (Chapter 2, Fig. 
3E&H) it was difficult to assess the individual potency of each swIFITM, especially since IFITMs have 
been shown to act in a dose-dependent manner (Chaper 2, Fig. 3A). However, the fact that swIFITM3 
levels were considerably lower than swIFITM1a levels, yet both IFITMs showed comparable inhibition 
of IAV, we hypothesized that a combination between IFITM localization and abundance determines 
its antiviral potential.  
Finally, we determined the contribution of endogenous swIFITMs to the antiviral IFN response in 
porcine NSK cells. While the simultaneous knockdown of all swIFITMs had no impact on IAV titers in 
the absence of IFN, stimulation of cells with IFN prior to infection resulted in a 10fold increase in viral 
titers in swIFITM knockdown cells compared to control cells, highlighting the importance of swIFITMs 
in the antiviral activity of IFN in porcine cells (Chapter 2, Fig. 4).  
In summary, we established swIFITM proteins as potent viral restriction factors that constitute a 
significant part of the anti-IAV activity of IFN in porcine cells, a finding corroborated by the fact that 
swIFITM proteins are highly upregulated in pigs infected with various swine respiratory disease 
viruses [229].  
Although replicating in various species such as humans and pigs, aquatic birds are the main reservoir 
for IAV [1]. Low pathogenic avian IAVs (LPAI) replicate in the intestinal tract of aquatic but also 
gallinaceous birds  causing no or only very mild disease symptoms [38]. However, upon acquiring 
mutations in the HA0 cleavage site that facilitate the activation of HA by a much broader range of 
cellular proteases, viruses become highly pathogenic and are no longer restricted to the intestines, 
but also replicate in the lungs of infected animals, before ultimately spreading systemically if not 
contained by the host [235]. While chickens rapidly succumb to the infection with highly pathogenic 
avian influenza (HPAI) viruses, ducks efficiently control viral replication [236]. Smith et al [237] 
compared host responses mounted in ducks and chickens upon IAV infection and found that in ducks 
IFITM1, 2 and 3 were upregulated in lungs as well as intestines upon infection with a HPAI virus, 
while IFITM induction was negligible in chickens. These findings were corroborated by a study 
conducted by Blyth and colleagues [238] that showed a pronounced upregulation of IFITM proteins 
in lungs of ducks infected with a HPAI virus. Duck IFITM3 was subsequently reported to restrict the 
replication of LPAI viruses of avian as well as mammalian origin. Interestingly, no anti-IAV activity was 
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observed for duck IFITM1, which harbored an extensive N-terminal insertion. It might be interesting 
to test whether duck IFITM1 evolved to counteract other pathogens infecting ducks. Although 
chicken IFITMs were not found to be upregulated by IAV infection in vivo [237], possibly due to the 
lack of RIG-I (a sensor of viral RNA) in chicken cells [239], chicken IFITM3 was found to be induced 
upon IFNα-stimulation and to reduce IAV titers when overexpressed in chicken fibroblast cells [240]. 
In the future, in order to determine the in vivo relevance of IFITM proteins in chickens beyond IAV 
restriction, it might be worthwhile testing the IFITM induction upon challenge with pathogens that 
are recognized by the cell in the absence of RIG-I. In addition, to identify whether IFITM expression is 
decisive in controlling HPAI infection in ducks as compared to chickens it might be interesting to 
infect ifitm3-/- ducks with HPAI viruses. 
Finally, considering the recent identification of bats as an alternative reservoir of IAV-like viruses [9, 
10], one study reported the presence and antiviral activity of IFITM3 in Myotis myotis, a bat species 
known to be susceptible to infection with several highly pathogenic viruses [241].  
Altogether, multiple studies assessing the antiviral potential of IFITM proteins present in species 
involved in zoonotic IAV transmission established these proteins as potent antiviral factors restricting 
IAV infection. IFITM proteins thus represent a major barrier that zoonotic as well as non-zoonotic 
IAVs have to overcome when infecting their hosts. 
 
 
4.3 ASSESSING THE ROLE OF IFITMS DURING LATE STAGES OF THE INFLUENZA A VIRUS LIFE 
CYCLE 
In order to efficiently interfere with viral replication, different ISGs evolved to target presumably 
every step of the viral life cycle. While ISGs differ in their antiviral activity with some antiviral 
proteins showing only modest viral restriction capacity when expressed in isolation, their concerted 
upregulation enables the efficient elimination of invading pathogens [242, 243].  
Several ISGs have been reported to be involved in late stages of the IAV life cycle, among them 
tetherin and viperin. Originally identified as antiviral factor inhibiting the release of retroviral 
particles [244], tetherin has later been shown to target a broad variety of enveloped viruses 
comprising filoviruses, rhabdoviruses, herpesviruses and arenaviruses [245]. Tetherin harbors an N-
terminal cytosolic domain followed by a transmembrane and an extracellular coiled-coiled domain. A 
glycophosphatidylinositol (GPI) moiety is attached to its C-terminus, anchoring the protein to 
membranes, similar to its transmembrane domain [246]. Tetherin occurs as disulfide-linked dimers 
[247]. By incorporation of its transmembrane domain into virions while its GPI anchor remains 
inserted into the host cell membrane (or vice versa) tetherin can tether newly budded virions to the 
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cellular surface, thereby blocking their release. Alternatively, since tetherin comes in dimers, one 
tetherin molecule might also have both, transmembrane domain and GPI anchor, embedded in a 
virion’s membrane, tethering the virion to the cellular surface by interacting with another tetherin 
molecule that is anchored to the host cell membrane [246]. Tetherin is antagonized by Vpu, an HIV-1 
accessory protein that induces tetherin surface downregulation, degradation and deplacement from 
nascent virions [244, 245]. To what extent tetherin affects the release of IAV virions remains a matter 
of debate. Initial studies showed that NA-dependent budding of IAV VLPs was enhanced when 
tetherin was either knocked-down by siRNA treatment or counteracted by the expression of Vpu, 
suggesting that IAV was negatively affected by tetherin [248]. However, most further studies, 
although confirming negative effects on VLP budding, did not detect a tetherin-mediated inhibition 
of wt IAV [249, 250]. While some authors suggested IAV might encode a tetherin antagonist similar 
to Vpu [249], others showed that HIV-1/IAV co-infections could not relieve tetherin’s block on HIV-1 
[251], implicating that either IAV did not encode a tetherin antagonist, or the antagonist was not 
functional in the context of HIV-1 infection. Finally, one study suggested that tetherin-mediated IAV 
restriction was strain-dependent, showing that certain HAs could alleviate tetherin’s negative effect 
on VLP budding [252]. The authors of this study thus hypothesized that strain-specific differences in 
HA and NA packaging on the virus’ surface that have been described before [253] might contribute to 
differential tetherin sensitivity. Strains incorporating more HA and NA molecules might sterically 
impede tetherin incorporation, thereby evading its viral restriction. Interestingly, several studies 
reported the incorporation of tetherin into VLPs, but not into wt IAV [249, 250], so one might 
hypothesize that HA and NA packaging might be less dense in VLPs compared to wt virus, rendering 
VLPs more susceptible to tetherin-mediated restriction. 
Viperin has been described to interfere with the life cycle of various viruses at different steps. Its 
interaction with the Dengue virus NS3 protein has been shown to inhibit viral replication [254], while 
its binding to farnesyl diphosphate synthase (FPPS), an enzyme catalyzing the formation of a 
precursor of cholesterol and thus important for the generation of lipid rafts, has been linked to HIV 
[255] as well as IAV [256] budding defects. While the viperin-mediated disruption of lipid rafts 
decreased the release of IAV particles in vitro [256], viperin-deficient mice showed neither an 
increase in viral loads nor pulmonary damage upon IAV infection [257].  
While IFITMs residing in target cells have been established as potent antiviral factors inhibiting the 
entry of a whole variety of different viruses [184, 190-194], their roles during late stages of the viral 
replication cycle have been discovered only recently [215-217]. Compton [215] and Tartour [216] and 
colleagues observed that IFITM proteins were incorporated into nascent HIV virions, thereby 
decreasing virion fusogenicity in a dose-dependent manner. They hypothesized that biophysical 
properties of membranes harboring IFITM proteins (decreased fluidity, increased positive curvature) 
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are responsible for this effect. In contrast, while Yu and colleagues [217] also observed IFITM 
incorporation into HIV virions, they found no correlation between the amount of IFITM incorporated 
and the extent of the decrease in virus fusogenicity. However, they detected an interaction between 
IFITM proteins and Env, most distinct for IFITM2 and 3, that resulted in impaired Env processing and 
incorporation.  
Given the strong negative effect IFITMs exert on IAV entry, we wondered whether IAV was also 
affected by the presence of IFITM proteins during late stages of its replication cycle. Indeed, we could 
show that IFITM3 was incorporated into IAV, IAV VLPs and HIV VLPs pseudotyped with IAV HA and 
NA (Chapter 3, Fig. 1B, 3C & 5A), and that this incorporation went along with a decrease in VLP 
envelope glycoprotein content. HIV VLP and IAV VLP entry capacity was found to be significantly 
reduced upon presence of IFITM3 in VLP producer cells (Chapter 3, Fig. 1E&F, 3B). In agreement with 
our observation that IFITM3 reduced VLP envelope levels, we could show for IAV VLPs that the 
negative effect IFITM3 exerted on VLP infectivity was alleviated in a dose-dependent manner when 
increasing amounts of HA were co-transfected into VLP producer cells. Whether IFITM3 interacts 
directly with HA similar to the interaction described for IFITM3 and HIV Env [217], or whether IFITM3 
competes with HA for incorporation into cellular membranes remains to be discovered.  
Surprisingly, in contrast to VLPs, wt IAV was not negatively affected in its entry capacity upon IFITM3 
incorporation, although this was associated with a decrease in viral HA (Chapter 3, Fig. 5C). We 
provide experimental evidence that the IFITM3:HA ratio in virus producer cells might steer IFITM3 
sensitivity during late stages of the viral life cycle (Chapter 3, Fig. 5D). However, although IFITM3 
incorporation did not negatively impact on IAV infectivity, preliminary results suggest that the 
reduction in viral HA rendered the virus more neutralization-sensitive when incubated with an HA-
directed antibody (Chapter 3, Fig. 5E), potentially compromising the virus in an in vivo situation.  
Our study revealed interesting parallels between tetherin- and IFITM3- mediated restriction of VLPs 
versus wt virus. Both ISGs exerted negative effects on VLPs but not wt IAV. As mentioned above, this 
could be explained by HA/NA-mediated displacement of IFITM3 from VLP or viral membranes, which 
would be more efficient for wt virus, assuming that HA/NA packaging is more dense in wt IAV 
compared to VLPs. Alternatively, one might also hypothesize that IFITM3 incorporation into 
VLPs/virions increases the stoichiometry of entry (the number of HA trimers needed for viral fusion), 
since more energy might be required to induce fusion of a more rigid membrane that shows 
increased positive curvature. Again, hypothesizing that HA/NA-packaging is more dense in wt virus 
compared to VLPs, a wt IAV might more easily provide enough HA-trimers on its surface to 
successfully complete fusion, even in the presence of IFITM3. Future studies assessing HA/NA 
densities on wt IAV and VLPs will be needed to clarify this issue.  
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In summary, studies involving tetherin, viperin and IFITM3 establish lipid rafts as suitable sites to 
target late stages of the IAV life cycle. Tetherin and IFITM3 both localize to lipid rafts [202, 258]. 
While tetherin hampers viral particle release, IFITM3 negatively impacts virion infectivity. In contrast, 
viperin pursues a different strategy by disrupting lipid raft domains, thereby interfering with virus 
assembly and budding. 
Overall, we established IFITM3 as antiviral factor that targets IAV during late stages of its life cycle 
and suggest the IFITM3-mediated viral restriction to be more intricate than previously appreciated. 
One might speculate that the increase in positive curvature and the decrease in fluidity of 
membranes upon IFITM3 incorporation might reduce virus infectivity under certain circumstances, 
but that the interplay with envelope glycoproteins and potentially other cellular and viral factors 
adds more levels of complexity we are only starting to resolve. 
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After successful infection and replication of its genome in the nucleus of the host cell, influenza
A virus faces several challenges before newly assembled viral particles can bud off from the
plasma membrane, giving rise to a new infectious virus. The viral ribonucleoprotein (vRNP)
complexes need to exit from the nucleus and be transported to the virus assembly sites at the
plasma membrane. Moreover, they need to be bundled to ensure the incorporation of precisely
one of each of the eight viral genome segments into newly formed viral particles. Similarly, viral
envelope glycoproteins and other viral structural proteins need to be targeted to virus assembly
sites for viral particles to form and bud off from the plasma membrane. During all these steps
influenza A virus heavily relies on a tight interplay with its host, exploiting host-cell proteins for its
own purposes. In this review, we summarize current knowledge on late stages of the influenza
virus replication cycle, focusing on the role of host-cell proteins involved in this process.
Introduction
Influenza A virus (IAV) is the causative agent of a febrile ill-
ness in humans, commonly referred to as ‘the flu’. IAV
causes seasonal epidemics and sporadic pandemics, impos-
ing a huge burden on human health and economy.
IAV are enveloped viruses belonging to the family of Ortho-
myxoviridae, whose members are characterized by a
single-stranded segmented RNA genome of negative polar-
ity (Palese & Shaw, 2007). Unlike most other RNA viruses,
orthomyxoviruses replicate in the nucleus of the infected
cell (Cros & Palese, 2003). While nuclear replication con-
fers several advantages, such as access to the cellular splicing
machinery, the virus faces the challenge of overcoming the
nuclear envelope. Due to its small genome size of 13.5 kb,
IAV relies heavily on cellular factors to complete its life
cycle. In this review we focus on late stages of infection and
describe the interplay between the virus and its host in the
process of vRNP nuclear export, transport of viral proteins
to the assembly site, genome packaging, as well as budding
and release of virions.
Transport of viral components to the
assembly sites
vRNP transport
After successful transcription and replication of the viral
genome the so-called viral ribonucleoprotein (vRNP) com-
plexes that consist of the viral RNA (vRNA) which is encap-
sidated by the nucleoprotein (NP) and bound by the viral
polymerase complex (Fig. 1) need to be exported from the
nucleus and shuttled to the cell surface in order to be pack-
aged into budding virions. For specific export, vRNPs need
to be recognized in the nucleus and discriminated from
other RNA species. Discrimination of cRNA and vRNA
takes place in the nucleus and only vRNPs are exported into
the cytoplasm (Tchatalbachev et al., 2001). Likely, the viral
polymerase adopts different conformations depending on
whether it is associated with cRNA or vRNA, which might
facilitate recognition of vRNPs as cargo for nuclear export
(Tchatalbachev et al., 2001; Gerber et al., 2014). Further-
more, it has recently been suggested that vRNPs are not
exported individually as proposed earlier (Chou et al.,
2013), but instead as complexes consisting of two or more
genome segments (Lakdawala et al., 2014). Nevertheless,
export of fully assembled sets of vRNPs has not been
observed yet. Export of newly assembled vRNPs takes place
through the nuclear pore complexes (NPC), which is an
active process, dependent on the help of cellular factors, so-
called exportins (Pemberton et al., 1998). Exportins
recognize nuclear export sequences (NES) present in to-be-
exported proteins and facilitate their transit through the
NPC into the cytoplasm.
Studies indicate that the viral nuclear export protein(NEP)
plays a critical role during vRNP export: viruses that lack
NEP are not viable and interfering with the nuclear localiza-
tion of NEP reduces viral growth (O’Neill et al., 1998; Neu-
mann et al., 2000). Furthermore, microinjection of
antibodies targeting NEP into IAV-infected cells specifically
inhibits vRNP export (O’Neill et al., 1998). The amino acid
sequence of NEP is highly conserved between different
influenza virus strains, especially with regard to the C-ter-
minal a-helix (Paterson & Fodor, 2012). Within the C-
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terminal domain of NEP, the residue W78 has been identi-
fied to be important for the interaction with the nuclear
localization signal (NLS) of matrix protein 1 (M1) (Akarsu
et al., 2003). M1 is known to be required for export and the
NEP–M1 interaction appears to be critical for vRNP trans-
port (Martin & Helenius, 1991; Akarsu et al., 2003; Shimizu
et al., 2011). Introducing anti-M1 antibodies into IAV-
infected cells prevents shuttling of M1 into the nucleus and
leads to nuclear retention of NP (Martin & Helenius, 1991).
Thus, both viral proteins, M1 and NEP, appear to play
important roles during vRNP export. Their late synthesis
during the viral life cycle, mediated by suboptimal splicing
in case of NEP, may be a regulatory mechanism to time,
and then promote transport of vRNPs from the nucleus to
the budding zones (Chua et al., 2013; Hutchinson & Fodor,
2013). In addition, vRNP export by NEP and M1 is also reg-
ulated by a switch in the post-translational modification
pattern of M1: Early in infection M1 is ubiquitinated at
lysine 242. M1 then becomes sumoylated at the same lysine
during late stages, which seems to protect it from
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Fig. 1. vRNP export. vRNP export is primarily CRM1-dependent, occurs through the NPC, and is largely dependent on M1
and NEP. In this scenario, M1 and NEP connect the vRNP to the CRM1 export machinery according to the ‘daisy-chain’ or an
alternative model. Other cellular factors such as YB-1, hCLE and Hsc70 also associate with the to-be-exported vRNP within
the nucleus. vRNP export appears to be positively influenced by MAPK- and caspase signalling. AIMP2 promotes sumoylation
of M1 which enhances vRNP export. In the cytoplasm, the vRNPs accumulate at the MTOC and associate with cellular factors
such as HRB and STAU1. These factors, together with YB-1, facilitate the release from the CRM1 export machinery and medi-
ate trafficking of vRNPs towards the cell surface.
http://jgv.microbiologyresearch.org 2059
Assembly and egress of influenza A virus
Downloaded from www.microbiologyresearch.org by
IP:  130.60.54.66
On: Tue, 28 Feb 2017 13:38:09
proteasomal degradation and thereby leads to increased M1
levels and supports vRNP export (Wu et al., 2011). NEP has
also been identified to be sumoylated at late stages of infec-
tion (Domingues et al., 2015), and interestingly, the switch
in M1 modification from ubiquitination to sumoylation is
promoted by the tumour suppressor AIMP2, which in turn
binds NEP and is stabilized by its interaction with NEP
(Gao et al., 2015).
NEP contains two NES in its N-terminal domain and is
known to interact with the cellular b-exportin chromosome
maintenance region 1 (CRM1) (O’Neill et al., 1998; Neumann
et al., 2000; Iwatsuki-Horimoto et al., 2004; Huang et al.,
2013). Indeed, studies confirm that vRNP export is largely
dependent on CRM1 and its cofactor Ran-GTP as blocking
the CRM1-operated export pathway by leptomycin B largely
abrogates vRNP export in IAV-infected cells (Fukuda et al.,
1997; Elton et al., 2001; Ma et al., 2001; Watanabe et al., 2001).
It has been proposed that M1 and NEP function as adaptors to
bridge the association of a vRNP complex with the CRM1
export machinery: In this scenario, M1 associates with vRNPs
through an interaction with NP or through binding directly to
the vRNA (Elster et al., 1997; Ye et al., 1999; Baudin et al.,
2001; Noton et al., 2007). In addition, M1 interacts with NEP
(Yasuda et al., 1993; Akarsu et al., 2003; Shimizu et al., 2011).
NEP in turn is recognized by CRM1–Ran-GTP through its
NES [however, binding of NEP to CRM1 in the absence of
Ran-GTP occurs independently of the NES (Neumann et al.,
2000)], thereby enabling the CRM1-dependent transport of
the vRNP export complex through the NPC (Fig. 1) (Paterson
& Fodor, 2012). This model, referred to as the ‘daisy-chain
model’, was recently challenged by a study which reported that
the interaction between M1 and the vRNPs is dependent on
the presence of NEP. Via its C-terminal domain, NEP interacts
not only with M1 but also with the polymerase to provide an
additional binding site and support the M1–vRNP
association (Brunotte et al., 2014). These data argue for an
export complex in which the vRNP is bound by both M1 and
NEP, and highlight again the requirement of NEP for CRM1-
dependent export.
Of note, other studies suggest that other viral proteins play
substantial roles in vRNP export. For example, inhibition of
the CRM1 export machinery by leptomycin B caused perinu-
clear accumulation of NP, but did not affect the localization of
NEP or M1 (Elton et al., 2001). NP encodes three NES, one of
which is recognized by CRM1 (Yu et al., 2012), while the other
two are CRM1-independent and might enable vRNP export
independently of M1 and NEP. Also, M1 has previously been
proposed as master regulator of vRNP export (Whittaker
et al., 1996) and was able to mediate vRNP export in the
absence of NEP (Bui et al., 2000). M1 also possesses an NES,
which is not CRM1-specific. Mutations in this NES impair
nuclear export of M1 and NP (Cao et al., 2012). These data
suggest that vRNP export is not entirely dependent on NEP
and CRM1 and indicate that CRM1-independent transit
routes exist.
Cellular factors have also been shown to influence vRNP
export in IAV-infected cells (Fig. 1). For example, heat
shock cognate 70 (Hsc70) binds to the C-terminal domain
of M1 (Watanabe et al., 2006) and, more weakly, to NEP
with which it competes for binding to M1 (Watanabe et al.,
2014a). Due to its NES (Tsukahara & Maru, 2004), Hsc70
was suggested to promote CRM1-dependent nuclear export
of M1-bound vRNPs (Watanabe et al., 2008). Furthermore,
Y-box-binding protein 1 (YB-1) was recently shown to
associate with the vRNP export complex. vRNPs are bound
in the nucleus by YB-1, where it accompanies the viral gene
segments during their transport through the NPC
(Kawaguchi et al., 2012). YB-1 appears not to be involved
in vRNP export directly but instead exerts its function in
the cytoplasm where it plays an important role in the trans-
port of vRNPs to the apical cell surface (Kawaguchi et al.,
2012). Another example is the mitogen-activated protein
kinase (MAPK)-dependent signalling pathway, which stim-
ulates NEP-dependent vRNP export (Pleschka et al., 2001).
Furthermore, inhibition of caspase 3 leads to retention of
vRNPs in the nucleus and it was suggested that IAV-
induced caspase 3 activation increases the diffusion capacity
of the NPC, thereby promoting vRNP export (Wurzer et al.,
2003). Both, MAPK- and caspase 3-dependent pathways are
activated during late phases of infection and appear to act
independently to stimulate viral trafficking.
Following arrival in the cytoplasm, the vRNPs are transported
to the cell surface for packaging into progeny virions. Even
though diffusion of vRNPs towards the cell membrane has
been reported (Babcock et al., 2004; Amorim et al., 2011),
vRNP trafficking is generally believed to occur via Rab11- and
microtubule-dependent vesicular transport (Bruce et al., 2010;
Eisfeld et al., 2011a; Momose et al., 2011). Once in the cytosol,
vRNPs have been shown to associate with the microtubule
organizing centre (MTOC) (Momose et al., 2007; Amorim
et al., 2011; Kawaguchi et al., 2012). Four cellular factors have
been shown to be involved in these early steps of vRNP trans-
port to the cell surface: the human immunodeficiency virus
Rev-binding protein (HRB), Staufen 1 (STAU1), YB-1 and
hCLE/C14orf166. HRB interacts with NEP after vRNP export
in the perinuclear region late in infection (O’Neill et al., 1998;
Eisfeld et al., 2011b). Due to its GTPase activating protein
(GAP) domain, HRB was proposed to mediate release of
vRNPs from the CRM1–Ran-GTP export complex after its
transit through the NPC (Eisfeld et al., 2011b). This has not
been proven yet, but siRNA-mediated knockdown of HRB
results in retention of vRNPs in the perinuclear region (Eisfeld
et al., 2011b). This indicates that HRB is required to promote
apical shuttling of vRNPs in the cytoplasm. STAU1 is a cellular
factor involved in mRNA transport, for example it has been
implicated in transport of mRNAs to the site of their transla-
tion at the rough endoplasmic reticulum, and has been shown
to bind to a number of viral proteins (e.g. NS1, NP andM1) as
well as to viral mRNA and vRNA (Falcon et al., 1999; Marion
et al., 1999; Shapira et al., 2009; Watanabe et al., 2014b).
STAU1 co-localizes with vRNPs in the cytoplasm. Knockdown
of STAU1 expression does not affect viral replication, but
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reduces the amount of viral particles released from infected
cells indicating a role for STAU1 in vRNP transport (de Lucas
et al., 2010). Furthermore, YB-1, which associates with vRNPs
already in the nucleus, mediates the interaction of progeny
vRNPs with microtubules (Kawaguchi et al., 2012). Thus, YB-
1 is required for vRNP accumulation at the MTOC and medi-
ates, potentially in concert with HRB, the transfer of vRNPs to
the endosomal vesicular trafficking system for subsequent
transport to the plasma membrane. hCLE, a cellular tran-
scription factor, associates with vRNPs in the nucleus where it
promotes viral polymerase and Pol II activity (Huarte et al.,
2001; Rodriguez et al., 2011). Recently, it was shown that
hCLE interacts with vRNPs in the cytoplasm where it co-
localizes with Rab11, PA and NP (Rodriguez-Frandsen
et al., 2016). Interestingly, hCLE appears to remain attached to
vRNPs during further routing of the viral genome and is even
incorporated into budding viral particles (Rodriguez-Frandsen
et al., 2016). However, the function of hCLE binding to vRNPs
during vRNP transport and packaging remains to be
determined.
The Rab11-dependent recycling endosomal pathway plays
an important role in vRNP trafficking from the MTOC to
the cell surface and virion assembly (Fig. 2) (Bruce et al.,
2010; Jo et al., 2010; Amorim et al., 2011; Eisfeld et al.,
2011a; Momose et al., 2011; Avilov et al., 2012b). Recycling
endosomes transport endocytosed material from the plasma
membrane to apical or perinuclear recycling endosomes and
shuttle cargo back to the cell surface. Rab11 is a marker for
recycling endosomes that mediates vesicle transport along
cytoskeletal structures through interactions with down-
stream adaptor and effector proteins (Bruce et al., 2012).
Live-cell imaging using tagged vRNPs confirmed that
exported vRNPs localize to Rab11-positive vesicles through
a direct interaction of PB2 and active Rab11 (Amorim et al.,
2011; Avilov et al., 2012b). Concordantly, knockdown of
Rab11a abrogates apical vRNP localization in infected cells
and leads to retention of the vRNPs in the perinuclear region
(Eisfeld et al., 2011a). In the presence of Rab11, transport
occurs through intermittently directed movements of
vRNPs, which are dependent on an intact microtubule net-
work (Amorim et al., 2011; Avilov et al., 2012a). Indeed,
destabilization of microtubules using nocodazole has been
shown to disrupt vRNP accumulation at the MTOC as well
as shuttling of vRNPs to the plasma membrane (Momose
et al., 2007; Amorim et al., 2011; Eisfeld et al., 2011a). Fol-
lowing transport, the vRNPs reside in patches adjacent to
the plasma membrane (Eisfeld et al., 2011a; Chou et al.,
2013; Hutchinson & Fodor, 2013). The genome segments
then move to the budding zones for incorporation into viri-
ons. Interestingly, vRNPs appear to dissociate from Rab11
for insertion into the budzone (Eisfeld et al., 2011a) and
Rab11 has not been detected in progeny virions (Shaw et al.,
2008; Hutchinson et al., 2014). However, mechanistically it
is not clear how vRNPs are moved from Rab11-positive sub-
membranous patches into the budding area on the apical
plasma membrane.
Transport of viral envelope proteins
The structural proteins haemagglutinin (HA), neuraminidase
(NA) and matrix protein 2 (M2) are synthesized and folded
in the rough endoplasmic reticulum (ER) and then trans-
ported to the plasma membrane through the secretory path-
way (Fig. 2) (Doms et al., 1993). Both, HA and NA are
glycosylated along their route through the ER and Golgi
towards the apical cell surface (Deom & Schulze, 1985). HA
is synthesized as a precursor, HA0, which requires post-trans-
lational processing by proteases into HA1 and HA2 in order
to gain fusion activity. Proteolytic cleavage of HA0 takes place
either in the trans-Golgi network (TGN) or at the cell sur-
face. Cleavage is mediated by a variety of cellular proteases
depending on the cell type as well as the type (mono- versus
polybasic cleavage site) and sequence of the cleavage site pres-
ent in HA [reviewed in (Bottcher-Friebertshauser et al.,
2013)]. Within the TGN, M2 is critical to ensure conforma-
tional stability of HA: Through its ion channel activity, M2
regulates the pH-balance between the cytoplasmic and trans-
Golgi compartment which is important to prevent premature
pH-induced changes in the HA conformation (Ciampor
et al., 1992; Grambas & Hay, 1992; Sakaguchi et al., 1996).
Indeed, the pH stability of HA and the activity of the ion
function of M2 were found to be inversely correlated in a
study by Grambas & Hay (1992).
HA and NA contain apical sorting signals in their trans-
membrane domains (TMDs) (Kundu et al., 1996; Lin et al.,
1998; Barman & Nayak, 2000), targeting them for transport
to the cell surface after synthesis in the ER. The coat protein
I (COPI) complex, which is involved in vesicle transport of
cargo between the Golgi and ER, was recently shown to be
involved in apical targeting of the viral structural proteins
HA, NA and M2 (Sun et al., 2013). In addition, the Rho
GTPase Cdc42 was suggested to promote apical transport of
NA (Wang et al., 2012). It is believed that both, HA and NA
are associated to sphingolipid-, cholesterol-rich membrane
patches (lipid raft microdomains) already during their trans-
port through the TGN as well as after insertion into the api-
cal membrane (Scheiffele et al., 1997; Simons & Ikonen,
1997; Barman & Nayak, 2000). The TMD of the viral glyco-
proteins and their cytoplasmic tail (CT) were both shown to
be required for lipid raft association (Barman & Nayak,
2000; Zhang et al., 2000b; Chen et al., 2005). Co-expression
of HA and NA led to their accumulation in lipid rafts and
accelerated their transport to the cell surface, which could
indicate that clustering of lipid rafts contributes to HA and
NA shuttling (Ohkura et al., 2014). This is in line with previ-
ous studies that argue for a requirement of lipid rafts for api-
cal targeting of HA and NA (Scheiffele et al., 1997; Keller &
Simons, 1998; Ohkura et al., 2014). The dependency on lipid
raft association for apical targeting might be virus strain-
dependent, as other studies report only a weak delay of gly-
coprotein transport upon mutating the TMD or CT
(Simpson & Lamb, 1992; Zhang et al., 2000b; Takeda et al.,
2003).
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Fig. 2. Apical transport of viral components. vRNPs are transported in a microtubule-dependent manner on Rab11-positive
recycling endosomes from the MTOC towards the cell surface. vRNPs associate with GTP-bound Rab11 through interactions
with PB2. On these vesicles, vRNP sorting and bundling is believed to occur before complete genome sets are incoporated
into budding virions. hCLE associates with vRNPs in the nucleus, remains attached to vRNPs during cytoplasmic trafficking
and is incorporated into virions. Structural viral proteins, such as HA, NA and M2 are synthesized in the ER and are transported
to the budding sites through the secretory pathway with the help of cellular factors such as UBR4. HA and NA are associated
with lipid raft structures from which M2 is largely excluded. HA maturation is mediated through cleavage by several cellular pro-
teases which are present in the trans-Golgi network, at the cell surface or the extracellular space. Other structural viral compo-
nents (M1 and NEP) travel to the budding sites along with vRNPs or might be recruited by cellular factors such as the F1Fo-
ATPase which binds to NEP.
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M2 is excluded from these lipid raft microdomains (Leser &
Lamb, 2005) and an apical sorting signal in M2 has not
been identified. Nevertheless, in infected cells M2 is also
targeted to the apical membrane in an actin-dependent
manner where it clusters with HA (Hughey et al., 1992;
Thaa et al., 2010). A recent study that combined a meta-
analysis of genome-wide RNAi screens with a screen for
interaction partners of the different viral proteins identified
the ubiquitin ligase UBR4 (ubiquitin N-recognin domain-
containing E3 ligase 4) as a required host factor for IAV and
an interaction partner of M2 (Tripathi et al., 2015). Inter-
estingly, UBR4 positively influenced apical routing not only
of M2 but also of the viral glycoproteins. Knockdown of
UBR4 reduced M2 expression levels and viral particle pro-
duction indicating that UBR4 might be required to protect
M2 from degradation and to ensure delivery of viral com-
ponents to the budding zones at the cell surface (Tripathi
et al., 2015).
Despite M2 being co-transported with HA and NA, Rab11
was also shown to be involved in apical delivery of M2
(Rossman et al., 2010b). This could either indicate that the
transport of M2 is at least partially mediated by the Rab11-
dependent endosomal pathway or alternatively, Rab11
could affect M2 endocytosis and thereby impact the plasma
membrane levels of M2.
Transport of M1 and NEP
M1 does not contain an apical localization signal. However,
due to its ability to associate with lipids, vRNPs and the
other structural viral proteins, M1 might be co-transported
together with other viral components to the cell surface. In
fact, transport of the viral gene segments and M2 through
Rab11-containing vesicles might be linked by M1, which
binds to both, M2 and vRNPs (Noton et al., 2007; Chen
et al., 2008). It has been suggested that M1 stays attached to
vRNPs after export, which on one hand prevents re-import
of vRNPs into the nucleus (Martin & Helenius, 1991) and
on the other hand promotes association of vRNPs with
other viral components through interaction with M2 during
vesicular shuttling and after apical delivery (Eisfeld et al.,
2015).
Even though the majority of NEP is localized in the nucleus
and cytoplasm during late stages of the viral life cycle, small
amounts of NEP have also been detected at the apical
plasma membrane (Carrasco et al., 2004; Gorai et al., 2012).
This is in line with earlier studies showing that NEP is
incorporated into virions (Richardson & Akkina, 1991;
Shaw et al., 2008). It is not clear how NEP transport to the
cell surface occurs, but NEP could piggy-back on vRNPs
through its association with M1 (Yasuda et al., 1993). In
support of this model; NEP, M1 and NP were shown to co-
localize at the apical plasma membrane (Carrasco et al.,
2004).
Genome assembly and packaging
It is currently believed that packaging of vRNPs into virus
particles is a highly regulated process rather than a random
one. In order to generate infectious virions, the distinct
genome segments need to be sorted, bundled and inserted
into budzones at the plasma membrane. Several studies sug-
gest that sorting of vRNPs does not occur in the nucleus or
during budding, but rather during cytoplasmic transport of
the genome segments towards the cell surface (Takizawa
et al., 2010; Chou et al., 2013; Lakdawala et al., 2014). In
addition, neither HA nor M2 are required for co-
localization of gene segments of different identities (Chou
et al., 2013) which indicates that vRNP sorting takes place
prior to arrival at the budzone. It is not clear whether
vRNPs are sorted following the delivery of vRNPs from the
MTOC to Rab11-containing vesicles, during transport, or
upon accumulation of vRNPs in Rab11-positive patches in
the apical periphery (Eisfeld et al., 2011a; Chou et al.,
2013). Nevertheless, Rab11-positive membranes may serve
as a platform for the gathering of the distinct genome seg-
ments (often described as bundling), which could allow
reassortment as well as assembly of vRNPs into packaging-
ready bundles, which are then incorporated into budding
particles (Eisfeld et al., 2015).
For successful genome packaging, vRNPs need to be dis-
criminated from other viral and cellular RNAs. In addition,
the distinct genome segments are required to be identified
and bundled in order to ensure packaging of a complete
genome set. Many studies have reported that the informa-
tion for these processes lies within the vRNA sequence:
vRNP-specific genome sorting and bundling signals have
been identified in the vRNAs (Hutchinson et al., 2010;
Gerber et al., 2014). Concordantly, two vRNA-like mole-
cules derived from the same gene segment but encoding dif-
ferent reporter genes were shown to compete for
incorporation into virions (Inagaki et al., 2012). In addi-
tion, the idea of packaging signals present in the vRNAs was
strengthened by the finding that vRNA-derived defective
interfering vRNAs containing deletions compete with their
parental vRNAs for insertion into virions (Duhaut &
McCauley, 1996; Odagiri & Tashiro, 1997; Duhaut &
Dimmock, 2002). To date, many signals required for pack-
aging have been mapped to different regions of the vRNA
such as the highly conserved 3¢ and 5¢ UTR, the terminal
part of the coding regions as well as the central part of the
vRNA (Fujii et al., 2003, 2009; Watanabe et al., 2003; Dos
Santos Afonso et al., 2005; Liang et al., 2005; Muramoto
et al., 2006; Gog et al., 2007; Marsh et al., 2007, 2008;
Hutchinson et al., 2008, 2009; Ozawa et al., 2009; Wise
et al., 2011; Gavazzi et al., 2013). These studies show that
some packaging signals are universal for all vRNPs, while
others appear to be segment- or even virus strain-specific.
Such variations in packaging requirements between strains
can lead to genomic incompatibilities and incomplete pack-
aging. Indeed, reassortment occurs more frequently
between closely related virus strains compared to more
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distantly related viruses (Essere et al., 2013; Marshall et al.,
2013).
For genome bundling, interactions between the different
vRNPs are thought to be of importance. In fact, recent stud-
ies favour a model of selective and hierarchical bundling of
genome segments into supramolecular complexes prior to
incorporation into virions (Gerber et al., 2014). The organi-
zation of vRNPs within virions predicts direct connections
between the individual gene segments: vRNPs are organized
in a so-called ‘7+1’ pattern in which seven vRNPs are local-
ized around one central segment (Harris et al., 2006; Noda
et al., 2006; Fournier et al., 2012b; Noda et al., 2012).
Indeed, a linear organization network between vRNPs has
been described (Fournier et al., 2012a, b). Mutations in
packaging signals of one segment can affect the incorpo-
ration of other segments, which further supports the
existence of interactions between individual vRNPs (Marsh
et al., 2007; Hutchinson et al., 2008; Marsh et al., 2008;
Hutchinson et al., 2009; Fournier et al., 2012b). Interest-
ingly, interaction networks of vRNPs have been visualized
through 3D electron tomography and revealed the presence
of a transition zone at the tip of the budding virion which
indicates that vRNPs are incorporated as a supramolecular
complex in which the gene segments directly interact with
each other (Fournier et al., 2012a, b). Furthermore, differ-
ences in vRNP interaction between virus strains were dem-
onstrated (Gavazzi et al., 2013), suggesting that sequences
required for genome bundling might evolve independently
in distantly related virus strains (Gerber et al., 2014).
The 7+1 organization of the IAV genome is observed
particularly in budding virions (Fournier et al., 2012a, b;
Noda et al., 2012) and it is believed that one central gene
segment mediates structural assembly of the vRNP bundle
through interactions with the surrounding segments
(Hutchinson et al., 2010; Gerber et al., 2014). In line with
this model, many studies have shown that certain gene seg-
ments are of a higher regulatory order and more strongly
affect genome bundling compared to other segments
(Muramoto et al., 2006; Marsh et al., 2007, 2008; Hutchin-
son et al., 2008, 2009; Gao et al., 2012). This is supported
by the finding that two to three vRNPs of different identities
have been found to assemble already before nuclear export
(Lakdawala et al., 2014). Thus, for successful incorporation
of all eight genome segments, a two-step bundling process
is suggested, in which vRNPs of high hierarchical order
form a complex first within the nucleus. Following export,
the other vRNPs are added to the vRNP bundle in a second
step, which could potentially take place during transport on
Rab-11 platforms in recycling endosomes (Gerber et al.,
2014).
The efficiency and accuracy of vRNP packaging is still under
debate: Some studies found that packaging of eight different
segments is possible and that packaging of more than eight
segments is uncommon (Noda et al., 2006; Chou et al.,
2012). These data are indicative of efficient, regulated inclu-
sion of eight distinct genome segments into virions.
However, this has been questioned by the finding that at
low MOI (multiplicity of infection) most infected cells were
reported to lack expression of at least one major viral pro-
tein (Brooke et al., 2013). This could potentially indicate
that frequently genome segments are missing but it could
also be explained by incorporation of damaged or mutated
segments.
Budding and release of new virions
Different morphologies, ranging from spherical particles to
long filaments, have been described for influenza virions
(Palese & Shaw, 2007). Importantly, the particle
morphology seems to change when adapting influenza
viruses to tissue culture conditions: Laboratory-adapted
strains typically produce mostly spherical particles with a
diameter of about 100 nm as well as virions of pleomorphic
shape (Fig. 3). Clinical isolates of influenza viruses in con-
trast display a filamentous morphology and their virions
can be >1 µm in length (Mosley & Wyckoff, 1946; Choppin,
1963). In line with this difference between primary isolates
and laboratory strains, a recent study found that upon pas-
saging a laboratory-adapted, spherical virus strain in guinea
pigs filamentous morphology was selected for. In contrast,
passaging virus in embryonated chicken eggs, a method
routinely used to grow virus in the laboratory, favoured
spherical particles (Seladi-Schulman et al., 2013).
While the different shapes of virions have been described
structurally in detail, only little is known about the differen-
ces in assembly and budding for spherical versus filamen-
tous viruses. It has been demonstrated that not only M1 has
a major influence on the shape of the particle but also HA,
NA, M2 and NP have been suggested to impact virus mor-
phology (Bourmakina & Garcia-Sastre, 2003; Elleman &
Barclay, 2004; Rossman et al., 2010a; Bialas et al., 2014;
Chlanda et al., 2015). Given that, most up-to-date studies
on assembly and egress of influenza virus have been per-
formed with laboratory-adapted spherical virions, this
review will focus on budding of spherical virions.
Budding is a dynamic multistep process, which includes
clustering of viral components at the apical cell surface, bud
initiation, bud outgrowth, incorporation of the viral
genome and scission of the bud in order to release the prog-
eny virion. Studies on human broncheotracheal epithelial
(HTBE) cells, a model for the human airway epithelium,
revealed that virus budding occurs preferentially at the tips
of epithelial microvilli (Kolesnikova et al., 2013). It can be
speculated that the lipid and/or protein composition of the
membrane at these tips is particularly suitable for virus bud-
ding, but this hypothesis has not been analyzed yet. IAV
envelopes are enriched for sphingolipids and cholesterol
compared to the average lipid composition of the plasma
membrane (Gerl et al., 2012), supporting the idea of
lipid raft-dependent virus budding.
Generally, all structural components of the virus need to be
transported to the apical cell surface and clustered in lipid raft
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domains to initiate the budding process. The accumulation of
HA and NA at lipid raft microdomains in the plasma mem-
brane results in the formation of larger functional raft
domains for assembly and budding, the so-called budzone
(Schmitt & Lamb, 2005; Rossman & Lamb, 2011). The trigger
for bud formation is not known but most likely accumulation
of viral glycoproteins starts the budding process. Studies
investigating the budding of virus-like particles (VLPs) indi-
cate that individual overexpression of HA, NA or M2 can
mediate VLP formation (Chen et al., 2007; Lai et al., 2010).
However, during virus infection HA is not sufficient to com-
plete budding and therefore VLP budding appears not to
mimic IAV budding accurately (Nayak et al., 2009; Rossman
& Lamb, 2011). A recent study showed that the generation of
VLPs which morphologically resemble budding viral particles,
requires at least the expression of either HA or NA together
with M1 and M2 (Chlanda et al., 2015).
Besides the glycoproteins, also M1 plays a critical role during
budding. M1 is believed to interact with the plasma mem-
brane and HA, NA, M2 and NEP as well as with vRNPs
(Yasuda et al., 1993; Ali et al., 2000; Baudin et al., 2001;
Noton et al., 2007; Chen et al., 2008), which could be
required for reciprocal recruitment and organization of the
viral components in the budzone. M1 can form oligomers
(Zhang et al., 2012) and interactions of M1 with the plasma
membrane have been shown to be required for
multimerization (Hilsch et al., 2014). Formation of M1
oligomers below the plasma membrane provides structure
and sturdiness to viral particles (Harris et al., 2001; Calder
et al., 2010) and could in addition be required for bud elon-
gation (Rossman & Lamb, 2011). Furthermore, the interac-
tion of M1 with the CT of HA and NA was shown to be of
particular importance for virion morphogenesis (Jin et al.,
1997; Barman et al., 2004).
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Fig. 3. IAV budding. (a) Electron micrograph of budding IAV. Viral particles can be of spherical, rod-like or filamentous shape.
A549 cells were grown on 6mm carbon-coated sapphire discs. Cells were infected with A/WSN/33 MOI=2 and 16 h post-
infection, cells were fixed with 2.5% glutaraldehyde in 0.1M cacodylate buffer. Samples were processed for transmission elec-
tron microscopy (TEM) imaging using high pressure freezing. Images were acquired on a Phillips CM-100 TEM at the Center
for Microscopy and Image Analysis of the University of Zurich. Shown are representative images (magnification: 135 000
(upper image) and 24500 (lower image). (b) Cartoon. Viral particles form at budding sites on the apical cell surface. Accu-
mulation of HA and NA on lipid rafts on the plasma membrane stimulates bud formation and outgrowth. M1 stabilizes the viral
particles and might contribute to vRNP incorporation and recruitment of other viral components including M2. M2 plays an
important role in scission of virions from the cell surface. For release of progeny viral particles, NA breaks interactions between
HA and sialic acid-containing glycoproteins. Besides vRNP bundles and M1, also NEP and NS1 are components of IAV virions.
In addition, cellular factors such as ubiquitin, hCLE, CD9, CD81, annexins or cytosceletal components are incorporated into
viral particles.
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The assembled vRNP complexes accumulate in Rab11-
positive submembranous patches below the plasma mem-
brane. The importance of Rab11 for virus budding
has been demonstrated: knockdown of Rab11 and its effec-
tor FIP2 delays or stalls virus budding which is probably
due to defects in vRNP transport to the cell surface as dis-
cussed above (Bruce et al., 2010). Recruitment of the vRNP
complex into the budzone could take place through interac-
tions with other structural proteins that have already been
inserted into the apical membrane. The CTs of HA and NA
as well as that of M2 have been shown to be required for
efficient genome packaging into budding virions (Zhang
et al., 2000a; McCown & Pekosz, 2005; Iwatsuki-Horimoto
et al., 2006). Also, the interaction between M1 and M2 is
believed to be critical for the production of infectious viral
particles (McCown & Pekosz, 2005; Iwatsuki-Horimoto
et al., 2006; Chen et al., 2008; Grantham et al., 2010). In the
absence of other viral proteins, M2 is not part of lipid raft
microdomains in the plasma membrane (Zhang
et al., 2000b; Leser & Lamb, 2005). However, in the pres-
ence of viral proteins, M2 is recruited to the site of budding
and was shown to localize to the outer periphery of the bud-
zone of infected cells (Rossman et al., 2010a; Rossman &
Lamb, 2011). Several possibilities for the recruitment of M2
to lipid raft domains harbouring the budzone have been
suggested: The amphipathic helix, which is present in the
CT of M2 is required for localization of M2 at the budzone
(Roberts et al., 2013). M2 has been shown to interact with
cholesterol directly and to associate with cellular mem-
branes (Schroeder et al., 2005; Rossman et al., 2010a; Thaa
et al., 2011), which indicates that association with
cholesterol-rich domains might occur without the help of
other recruitment factors. Indeed, M2 clusters with larger
lipid raft domains, a process which was shown to be depen-
dent on palmitoylation of the CT (Thaa et al., 2011). In
addition, M2 is known to interact with M1 and HA (Chen
et al., 2008; Thaa et al., 2010), which might further promote
re-localization of M2 to the lipid raft structure of the bud-
zone. Importantly, M2 was reported to mediate pinching of
virus particles off the plasma membrane (Rossman et al.,
2010b). For membrane scission, membrane curvature at the
base of the budding virion needs to be induced and
concordantly, M2 localizes primarily to the neck of budding
virions (Rossman et al., 2010a; Roberts et al., 2013). The
conserved amphipathic helix of M2 mediates completion of
the budding process in a cholesterol-dependent manner
through its insertion into the lipid bilayer (Rossman et al.,
2010b). Indeed, the amphipathic helix was shown to be
capable of inducing a strong, negative Gaussian curvature at
the base of the bud which is required for scission of viral
particles (Schmidt et al., 2013). Pinched off viral particles
remain attached to the cell surface due to binding of HA to
sialic acid-carrying proteins. For virion egress, NA cleaves
off sialic acid residues on glycoproteins in proximity of the
budzone (Palese et al., 1974; Griffin et al., 1983). Only few
cellular factors have been identified to be required for IAV
budding. For example, the tetraspanin CD81 was shown to
be recruited to the budzone and to be incorporated into
progeny virions (Shaw et al., 2008; He et al., 2013). Knock-
down of CD81 results in altered virion morphology and
stalled detachment of particles from the plasma membrane
indicating that CD81 might be involved in the scission pro-
cess (He et al., 2013). Furthermore, the scaffolding protein
receptor for protein C kinase 1 (Rack1) was shown to inter-
act with a motif in the N-terminal part of M1 and this inter-
action was found to contribute to the release of virus buds
from the cell surface (Demirov et al., 2012). In addition, the
ATPase activity of the cellular F1Fo-ATPase was shown to
be important for the egress of budding virions (Gorai et al.,
2012). The F1Fo-ATPase associates with NEP and localizes
to the budzone during late stages of infection (Gorai et al.,
2012). While it is not yet known how the F1Fo-ATPase sup-
ports budding, it can be hypothesized that it contributes to
the induction of membrane curvature. For mitochondrial
F1Fo-ATPase it could be demonstrated that the polymeriza-
tion of dimers of the F1Fo-ATPase induces membrane bud-
ding, leading to cristae formation in the mitochondria
(Allen, 1995). It is therefore tempting to speculate that a
similar function of the F1Fo-ATPase at the plasma mem-
brane is usurped by IAV to initiate virus budding.
In summary and according to the model proposed by
Rossman and Lamb (2011), initiation of budding is medi-
ated by HA and NA which fulfil redundant functions.
Together with M1, recruitment of other viral proteins and
the genome results in virion assembly and bud elongation.
Inclusion of M2 to the neck of budding virions results in
incorporation of M2 into the virions as well as scission of
the viral particles. Therefore, budding is a much more com-
plex process than suggested by earlier VLP studies. Likely,
in the context of a viral infection, various interactions
between different viral components as well as support of
cellular factors are required to orchestrate budding.
Incorporation of cellular proteins into
virions
For many viruses it has been shown that in addition to
viral proteins, host-cell proteins can be incorporated into
virus particles [reviewed in (Cantin et al., 2005)]. It was
found that most of those proteins are associated with lipid
rafts, which are the budding sites for many viruses, such as
IAV, human immunodeficiency virus (HIV)-1, respiratory
syncytial virus (RSV) and others (Chazal & Gerlier, 2003).
While some incorporated proteins have been described to
be advantageous for the virus (e.g. cyclophilin A, a peptidyl
prolyl isomerase incorporated into HIV-1 particles, which
promotes capsid uncoating upon infection of the virus)
(Franke et al., 1994; Thali et al., 1994), some have been
found to decrease virus infectivity (e.g. APOBEC3G, a cyti-
dine deaminase, which induces hypermutation of the HIV-
1 genome) (Sheehy et al., 2002; Mangeat et al., 2003).
However, for most of the cellular proteins incorporated
into viruses, their functional significance remains to be
determined.
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The knowledge on cellular proteins which are incorporated
into IAV virions is limited. First, a proteomics study was
published in which cytoplasmic as well
as envelope-associated proteins present in purified IAV
were identified (Shaw et al., 2008). The identified host-cell
proteins were mostly cytoskeletal proteins, annexins, glyco-
lytic enzymes and tetraspanins, but their function for the
virus (or their antiviral role) has not been elucidated yet.
However, for some members of the annexin family and the
tetraspanins follow-up studies have addressed this question.
Annexin II has been shown to be incorporated into IAV
particles and to convert plasminogen into plasmin, enabling
proteolytic activation of HA in the absence of suitable cellu-
lar proteases (LeBouder et al., 2008). Recently, it was found
that annexin V is upregulated and translocated to the cell
surface upon IAV infection. Localizing to lipid rafts,
annexin V gets incorporated into IAV particles and is asso-
ciated with a decrease in g-interferon signalling in newly
infected cells, leading to an increase in viral replication
(Berri et al., 2014). Intriguingly, not only annexins but also
other host-cell proteins described to be incorporated into
IAV have been reported to be incorporated into other
enveloped viruses. Shaw et al. (2008) distinguish between
highly abundant cellular proteins that may be incorporated
unspecifically (e.g. b-actin or tubulin) and proteins
enriched at virus budding sites, such as lipid rafts. Whether
the virus chooses its budding site because of the presence of
specific beneficial proteins or whether incorporated pro-
teins just happen to be present at the virus budding site
remains elusive.
Hutchinson et al. (2014) added to the knowledge on cellular
proteins incorporated into IAV by performing proteomics
studies of IAV grown on either mammalian Madin–Darby
canine kidney (MDCK) and Madin–Darby bovine
kidney (MDBK) cells or in embryonated chicken eggs. They
detected the incorporation of a myriad of host-cell proteins
into IAV, many of which overlapped with previously described
proteins, namely cytoskeletal proteins, annexins, glycolytic
enzymes and ubiquitin (Franke et al., 1994; Thali et al., 1994;
Shaw et al., 2008). In addition, they described membrane pro-
teins, small GTPases and other signalling proteins previously
unaccounted for to be incorporated into IAV particles.
Intriguingly, some host-cell proteins, such as ISG15, were
uniquely found to be incorporated into IAV particles when
the virus was grown on MDCK cells. Other proteins, such as
the tetraspanin CD9, seemed to be functionally replaced by an
avian substitute when the virus was grown in eggs. These data
suggest that incorporation of certain host proteins is conserved
and required across different species, whereas others might
have species-specific roles.
Although some cellular proteins incorporated into IAV may
be functionally irrelevant, many of them might harbour
unanticipated functions and play important roles during
infection, providing the virus with host factors needed at or
shortly after viral entry into a susceptible target cell. In addi-
tion, as host factors stemming from one species may not be
functional in another, they have the potential to determine
the virus’ host range, which is of great importance for IAV
that is able to infect multiple species.
Table 1. Selected host factors with a described function during the late stages of IAV infection
Host factor Function Reference
Exportin vRNP nuclear export Pemberton et al. (1998)
CRM1/Ran-GTP vRNP nuclear export O’Neill et al. (1998), Neumann et al. (2000), Iwatsuki-Horimoto et al. (2004), Huang et al.(2013)
MAPK pathway vRNP nuclear export Pleschka et al. (2001)
Caspase 3 vRNP nuclear export Wurzer et al. (2003)
AIMP2 vRNP nuclear export Gao et al. (2015)
YB-1 vRNP trafficking Kawaguchi et al. (2012)
HRB vRNP trafficking O’Neill et al. (1998), Eisfeld et al. (2011)
Staufen 1 vRNP trafficking de Lucas et al. (2010)
microtubules vRNP trafficking Amorim et al. (2011), Avilov et al. (2012b)
Hsc70 vRNP trafficking Watanabe et al. (2006, 2014a)
hCLE vRNP trafficking Rodriguez et al. (2011), Rodriguez-Frandsen et al. (2016)
Rab11 vRNP trafficking
M2 trafficking
Bruce et al. (2012), Hutchinson & Fodor (2013)
Rossman et al. (2010b)
actin M2 trafficking Hughey et al. (1992), Thaa et al. (2010)
UBR4 Trafficking of HA, NA and M2 Tripathi et al. (2015)
COPI Trafficking of HA, NA and M2 Sun et al. (2013)
Cdc42 NA trafficking Wang et al. (2012)
cellular proteases HA activation Bottcher-Friebertshauser et al. (2013)
F1F0 ATPase Virus budding Gorai et al. (2012)
CD81 Virus budding He et al. (2013)
Rack1 Virus release Demirov et al. (2012)
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Conclusions
In summary, the roles of viral proteins and vRNA during
late stages of the infection have been studied in detail and
we have made progress in understanding the processes lead-
ing to the release of new virions. Also with regards to cellu-
lar proteins involved, several host factors have been
identified and characterized for their proviral function
(Table 1). However, many open questions remain: despite
tremendous progress and efforts we still only partially
understand the mechanisms guiding packaging of the
vRNPs. It is still unclear how M1 and NEP are transported
to the assembly sites and it is not well understood how
localization and assembly of the virion components at the
budzone are regulated, timed and organized. Moreover, for
technical reasons most studies have been performed with
laboratory-adapted IAV strains which differ in their mor-
phology from primary isolates and thus far, it is unclear
how the assembly and budding processes differ between
spherical and filamentous virions. It can also be assumed
that many more cellular proteins are usurped by IAV for
assembly and egress than currently known as hundreds of
cellular factors have been identified as required for the virus
but not been characterized yet (Stertz & Shaw, 2011;
Tripathi et al., 2015). Future studies are expected to reveal
novel insights into the tight interplay between the virus and
its host cell at late stages of the infection.
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